Category: Articles

This includes the analogous nature of articular cartilage, muscle fascia, and intervertebral disc confirmed by way of comparative Scanning Electron Microscope analysis

PENSACOLA, Fla., Aug. 15, 2022 /PRNewswire/ — Regenative Labs, a leading HCT/P manufacturer, has co-authored a pioneering paper together with experts from The Institute of Regenative Medicine and the Department of Pharmacology and Chemical Biology, Baylor College of Medicine.

 

“This paper is a market disruptor and will be our most significant paper released to date. This is the first literature that we are aware of to utilize Scanning Electron Microscope (SEM) images of actual tissue samples to objectively demonstrate on a qualitative and quantitative basis that collagen structural tissue matrices in our post-processed Wharton’s Jelly allografts and those in articular cartilage, muscle fascia, and intervertebral discs are analogous,” said Regenative Labs CEO, Tyler Barrett.

 

This research highlights our commitment to the Regenerative Medicine community. We believe the combination of our IRB-approved observational studies, peer-reviewed publications, ISO-certified laboratory processes, and our commitment to compliance with FDA and American Association of Tissue Banks (AATB) standards, sets the standard for HCT/P manufacturers. Regenative Labs has pioneered the use of perinatal tissue allografts and is pleased that this paper supports our current homologous use practices, consistent with our 361 status.

 

Currently, the treatments for the Intervertebral Disc (DDD) range in cost and effectiveness from an $8 bottle of Ibuprofen to $150,000 for spinal fusion (1). Neither of these treatment options target the foundational issue of ECM cartilage breakdown in the intervertebral discs. By age 35, 30% of people show signs of DDD; by age 60, this increases to 90% (2). That we are aware of, this is the first perinatal tissue allograft in the medical marketplace that may be applied in a homologous fashion per FDA 361 guidelines to replace or supplement missing or damaged connective tissue. All other non-surgical paradigms focus on symptom management and do not address the disc’s collagen structural degeneration. In collaboration with medical providers across the country, we are actively investigating additional homologous use applications for this technology in tissue defects associated with the load-bearing joints of the knee, hip, shoulder, spine, ankle, and foot.

 

Billions of dollars are spent annually on the surgical care and treatment of patients suffering from degeneration of load-bearing joints and intravertebral discs. We are honored to offer patients evidence-based and structural tissue defect-specific non-surgical applications on a global scale.

 

Additional Sources:

1. How much does degenerative disc treatment cost? CostHelper. (n.d.). Retrieved August 10, 2022, from https://health.costhelper.com/degenerative-disc.html
2. Degenerative disc disease. Columbia Neurosurgery in New York City. (2021, July 21). Retrieved August 10, 2022, from https://www.neurosurgery.columbia.edu/patient-care/conditions/degenerative-disc-disease

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs’s expert product research and development team complies FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

New Financing to Meet Significant Growth in Global Demand for MolecuLight’s i:X® and DX™ Point-of-Care Imaging Devices for the Wound Care Industry

 

TORONTO, Aug. 11, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced that it has completed a financing with BDC Capital and iGan Ventures. The funds are to support MolecuLight’s continued global expansion to meet growing customer demand for its MolecuLight i:X® and DX™ devices. Leonard Kofman and Jody Staggs, Managing Director of SWK Holdings will join MolecuLight’s Board of Directors as observers.

 

“With the continued growth in global demand for our i:X and DX platforms, we are happy to announce this financing from BDC Capital and iGan Ventures, who has been an early investor in MolecuLight,” says Anil Amlani, CEO of MolecuLight Inc. “The proceeds will support the continued growth of our commercial operations and infrastructure to meet market demand”.

 

“We have invested in MolecuLight since inception and are thrilled to see the company achieve global commercial success,” says Sam Ifergan, Founder and President of iGan Partners. “Their customers continue to generate a wealth of published data showing the improved outcomes and cost savings, which is supporting MolecuLight becoming the standard-of-care in wound care globally”.

 

“BDC is proud to participate in the financing of MolecuLight, an impressive Canadian company that is making a global impact in terms of improving healthcare outcomes,” says Leonard Kofman, Partner with BDC Capital’s Intellectual Property-Backed Financing practice. “MolecuLight solved an unmet clinical need – the need to detect bacterial burden in wounds, and has commercialized a suite of products that is positively impacting wound care globally. Demand for the technology is strong and growing and we believe the company is well positioned for continued growth and success”.

 

The MolecuLight devices are sold in North America through its direct sales and clinical applications team and internationally through MolecuLight’s 15 specialized distributors in 18 countries.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which include two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

 

Tungsten Advisors served as the exclusive financial advisor to MolecuLight Inc.

 

About BDC Capital
BDC Capital is the investment arm of BDC, Canada’s bank for entrepreneurs. With over $3 billion under management, BDC Capital serves as a strategic partner to the country’s most innovative firms. It offers a full spectrum of capital, from seed investments to transition capital, supporting Canadian entrepreneurs who wish to scale their businesses into global champions. Visit bdc.ca/capital.

 

About iGan Partners:
Based in Toronto, iGan Partners is Canada’s leading health technology investors focused on disrupting the sector through breakthrough innovation that dramatically improve patent are while reducing costs. The firm focuses on identifying at an early-stage, then commercializing and scaling technological advancements in AI/Cloud-enhanced medical devices and digital health. iGan provides portfolio companies with smart-capital, active support, and access to a network of industry partners and sector-specific co-investors to help them grow and succeed.

 

About Tungsten Advisors:
Tungsten Advisors (www.tungstenadv.com) is an investment banking firm focused on strategic advisory and corporate finance for healthcare and technology companies. Tungsten provides transactional services including financings (private placements/PIPEs), corporate licensing and mergers and acquisitions (M&A). Tungsten also focuses on company incubation and makes direct investments alongside the creation of new companies in healthcare and technology.

 

Securities offered through Finalis Securities LLC Member FINRA/SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors and Finalis Securities LLC are separate, unaffiliated entities.

 

SOURCE MolecuLight

Future applications for the early, preventative use of amniotic membrane allografts in addition to the current standard of care for DFUs present a novel opportunity to reduce long-term morbidity and amputation risk in diabetic patients.

 

PENSACOLA, Fla., Aug. 8, 2022 /PRNewswire/ — A new MDPI study, co-authored by Regenative Labs signifies a huge win for patients suffering from diabetic foot ulcers (DFUs). DFUs are debilitating for an individual. They are painful, long lasting, and, even with proper care, can lead to amputation. The current standard of care for DFUs is debridement, the medical removal of dead, damaged, or infected tissue to improve the healing potential of the remaining healthy tissue. The increased healing time and augmented risk of amputation associated with the current standard of care only solidifies the need for new DFU treatment alternatives. Regenerative medicine is such an alternative.

 

With approximately 37.3 million diabetic adults in the United States, physicians are faced with an epidemic. Given the projected increase of 1.4 million new diagnoses of diabetes mellitus each year, advancing knowledge and care for the disease and its related conditions is especially relevant.

 

Regenative Labs’ AmnioText™, a dehydrated amniotic membrane allograft, was used to close a grade 5 wound according to the Curative Health Services (CHS wound grade scale), described as full thickness and subcutaneous tissues, exposed tendons, ligaments, and/or joints, plus necrotic tissue in the wound, in 7 weeks. Grade 5 wounds have a 91.5% rate of not healing at all. This unsettling outcome emphasizes the efficacy and importance of amniotic membrane allografts in revolutionizing the standard of care for DFUs.

 

The inability to heal DFUs presents a severe danger to patients as anywhere from 5 to 24% of untreated DFUs can lead to limb amputation within 6–18 months. These infections can lead to long-term impairment and possible lower-limb amputation without timely and correct management.

 

“Regenative Labs and our products are focused on ameliorating this problem with our outcomes-based approach. We provide the highest quality amniotic membrane allograft to allow doctors to provide predictable outcomes for their patients,” shared Regenative Labs CEO, Tyler Barrett.

 

Amniotic membrane allografts, such as those provided by Regenative Labs, have proven to augment the body’s ability to regenerate the structural tissue defects associated with DFUs; they are also comparable in cost to the standard of care, which averages about USD 17,245. Not only is the current standard of care for DFUs less effective, but it is also high in cost and typically relies on inpatient expenditures.

 

Medicare now recognizes the medical necessity of amniotic membrane allografts in the treatment of both DFUs and venous stasis ulcers. Consequently, many patients rely on Medicare to assist with the costs associated with DFU treatment. This presents the opportunity for human amniotic membrane allografts to be utilized in rural and underserved communities where DFU treatment is typically delayed due to high costs and a lack of supplies associated with traditional treatment. This could exponentially decrease the risk of amputations in diabetic patients in these rural and underserved communities.

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines.

 

Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

PENSACOLA, Fla., Aug. 1, 2022 /PRNewswire/ — Regenative Labs, a leading HCT/P manufacturer, and AAPC, the nation’s largest medical coding, training, and certification association, are pleased to announce a strategic healthcare compliance collaboration. By combining AAPC’s medical training and credentialing expertise with Regenative Labs’ human tissue allografts, together both organizations will support the pioneering of the first Wharton’s jelly allografts to be assigned a Q code and be approved for application directly to a defect using a syringe.

 

“This is an important step in furthering the mission of educating providers and elevating healthcare outcomes and we’re proud to be a part of it,” shared AAPC CEO, Bevan Erickson.

 

Regenative Labs received approval from the Centers for Medicare & Medicaid Services (CMS) to cover CoreText™ and ProText™, the first Wharton’s jelly allograft products recognized as a 361 HCT/P by CMS regulated under 21CFR 1271.10, establishing a new Level II HCPCS code Q4246 “CoreText or ProText, per cc.” According to CMS, both solutions provide the extracellular matrix needed for the infiltration, attachment, and proliferation of cells required to repair damaged tissue. They are typically used for muscle and cartilage tears and help repair damaged tissue due to wounds and tissue defects and are applied directly to the defect using a syringe.

 

Regenative Labs, now seeking to collaborate to further HCT/P compliance, recognizes the value AAPC brings to the healthcare industry as the world’s leading healthcare association, with more than 200,00 members and 30+ years of supporting healthcare professionals, providers, payers, and health systems

 

AAPC will deliver healthcare providers important coding resources, including full skeletal illustrations and applicable DX codes for Regenative Labs Wharton’s jelly allografts products for specialties, including Orthopedics, Pain Management, Podiatry, and Rheumatology. In addition, AAPC will create a customized web-based training module to ensure providers understand how to utilize more specific homologous applications with current DX codes to support accurate procedural reimbursement for these products.

 

“We look forward to the clarity this collaboration will bring to the market allowing proper documentation of homologous use applications,” said Regenative Labs CEO Tyler Barrett.

 

Regenative Labs firmly believes that no other organization understands coding regulations and documentation requirements better than AAPC, leading AAPC to be the right partner for this important project.

 

About AAPC: AAPC’s mission is to advance the business of healthcare by providing professional training, industry-standard certifications, and comprehensive solutions to individuals and organizations across medical coding, billing, auditing, compliance, and practice management. As the most trusted source for driving accuracy, profitability, and peace of mind, AAPC helps healthcare organizations reach the full potential of their revenue cycle. Learn more at AAPC’s website: www.aapc.com

 

About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

 

SOURCE Regenative Labs

 

This article was originally published here

Joins Cerner Code Program

WoundZoom Digital Wound Management solution now available in Cerner’s App Gallery

 

STEVENS POINT, WI – July 27, 2022 – Perceptive Solutions, Inc., developer of WoundZoom Digital Wound Management, today announced its integration partnership with Oracle Cerner and the availability of WoundZoom in the Cerner Code Program App Gallery. This partnership provides a secure and reliable exchange of wound care data between WoundZoom and a facility’s Cerner EHR system.

 

Perceptive Solutions joins the Cerner Code Program as a trusted integration partner so our customers can leverage the benefits of our validated application, WoundZoom, while eliminating additional steps in their workflow. Data captured using WoundZoom at the bedside, such as precise wound measurements, images, and clinical assessments automatically sync to patients’ charts, creating a more efficient workflow and a complete patient record in the EHR.

 

“Our innovative digital wound management solution enables clinicians to spend more time with patients through automated charting, wound imaging, and elimination of the manual measurement process. Cerner is a leading EHR provider for inpatient facilities and we are excited to provide accessibility of WoundZoom to Cerner customers,” said Mark Lacerte, President of Perceptive Solutions. “The technology integration through Cerner’s validation process enables a secure and reliable data flow from our solution into Cerner’s clinical charts. This enables healthcare facilities to more efficiently share valuable wound care data between both clinical and administrative team members within their EHR.”

 

About Perceptive Solutions

Perceptive Solutions modernizes the practice of wound care with technology-enabled systems designed to increase clinical efficiency, improve care quality, and mitigate risk. Integrating smoothly with your EHR, WoundZoom utilizes the latest AI and imaging technology to capture accurate wound images and measurements from your smart device, automatically prompt and document appropriate actions, and create a continuous, standardized clinical record across shifts, floors, and facilities. For more information, visit https://perceptivesol.com/.

 

Media Contact
Karen Guzdzial
Director of Marketing
(727) 225 7944
karen.guzdzial@woundzoom.com

Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

 

LEEDS, UK and TORONTO, July 13, 2022 /PRNewswire/ – MolecuLight Inc., the leader in fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced the publication of an independent, blinded randomized controlled trial in Diabetes Care. The publication on this 56-patient trial, titled “The use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial“1 reported that the use of a MolecuLight i:X® device to visualize the presence of elevated bacterial burden in wounds doubled 12-week wound healing rates (204%) in diabetic foot ulcer patients over standard-of-care alone.

 

Diabetes is a significant global health ailment: over 416 million people have diabetes worldwide2 and 25% of these patients develop a diabetic foot ulcer (DFU)3, greatly diminishing quality of life and increasing the need for costly and extended treatment. In the UK, the NHS spends £1 billion ($1.25 billion US) annually on DFU care and management24.

 

“As a clinician in wound care, especially when managing patients with chronic wounds, the holy grail is improvement in wound healing rates”, says David Russell, Associate Professor in Vascular Surgery at University of Leeds and lead author in the study. “In our randomized controlled trial, the results were impressive – the use of a MolecuLight device to inform our wound care decision-making helped us double the number of wounds that were healed at 12 weeks. This has benefits for the patient and our healthcare system.”

 

Patients were stratified into two groups, one in which the MolecuLight device was not used, and one in which clinicians used the MolecuLight device bi-weekly to assess diabetic foot ulcers for the presence of elevated bacterial burden. For the MolecuLight group, fluorescence imaging was performed after treatment. Fluorescence indicated the presence of elevated bacterial burden in over 80% of the wounds. Additional treatment based on imaging findings was performed as the discretion of the clinician, and most often included further debridement focused on the regions with elevated bacterial loads. Importantly, there was no increase in antibiotic prescribed in the MolecuLight group.

 

Alongside the impressive 2-fold improvement in healing rates, this study showed an association between baseline fluorescence and wound outcomes. Of the patients with negative fluorescence images at the baseline visit, 53.9% healed at 12-weeks, versus 37.5% with positive baseline fluorescence images. In other words, patients were 36% less likely to heal at 12 weeks if their wound was positive for high bacterial loads at the beginning of their treatment, as depicted by MolecuLight. Wound area reduction was superior in the MolecuLight arm and patient quality of life diverged toward improvement in the MolecuLight arm at 4 weeks and toward deterioration in the control arm at 12 weeks.

 

“To improve decision-making and care with DFU patients we must be able to measure what we manage. The MolecuLight i:X, as illustrated by the results in this RCT, is a powerful tool for screening DFUs for infection as well as monitoring new or worsening bacterial burden over time”, says David G. Armstrong, Professor of Surgery, Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at Keck School of Medicine of the University of Southern California as well as the US-appointed delegate to the International Working Group on the Diabetic Foot (IWGDF). “This new study provides further data for the improved healing rates and improved patient care that can be achieved in a clinic with routine use of fluorescence imaging to detect wound bacteria.”

 

“We congratulate Dr. Russell and the team at Leeds for their excellent study and publication that shows the utility of MolecuLight to detect elevated bacterial burden and to inform clinical decision-making at the point-of-care”, says Anil Amlani, MolecuLight’s CEO. “A doubling of 12-week wound healing is a significant outcome and is consistent with what thousands of wound care clinicians are experiencing worldwide, that MolecuLight enables clinicians to deliver superior, proactive bacterial/infection management that improves wound outcomes”.

 

The Leeds Diabetes Limb Salvage service is now using the MolecuLight device to image all patients with wounds that are failing to achieve a healing trajectory within 4 weeks. To help manage patient volumes, patients who are negative with MolecuLight are triaged, and are then referred to community care as their wounds are considered manageable and able to achieve a healing trajectory.

 

This new RCT is part of a broad body of clinical evidence showing the many benefits of the MolecuLight i:X and DX devices across the range of wound care applications to help inform and improve clinical decision-making. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

 

1. Rahma S et al. Diabetes Care 2022;45(7):1601–1609
2. Diabetes UK: Diabetes Prevalence, www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2019
3. Armstrong AG et al. The New England Journal of Medicine, 2017; 376:2367 – 75
4. Kerr, M, 2017, www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

For more information, contact:
Rob Sandler
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

The platform serves as a comprehensive resource for podiatry news and information to aid clinical decision-making and improve patient outcomes

 

MALVERN, Pa., July 12, 2022 /PRNewswire-PRWeb/ — As healthcare professionals across the podiatry community manage an ever-changing and complex field, HMP Global, the leading healthcare event and education company, today announced the launch of two value-added offerings, PodiatrySource and the Podiatry Learning Network.

 

The Podiatry Learning Network serves as the premier digital hub for podiatrists and offers direct access to clinically relevant news and information, expert perspectives, and continuing education. The network joins HMP Global’s portfolio of well-respected learning platforms dedicated to serving as online information hubs, and is a singular destination offering practical, relevant content and education guided by podiatry professionals.

 

Visitors to the new network can create a customized experience, selecting topic preferences most pertinent to them; receive regular e-mail updates with breaking news and carefully created content; grow professionally with the network’s repository of education; and connect with other podiatry colleagues around the world through the platform’s networking options.

 

“With the creation of the Podiatry Learning Network, HMP Global is delivering a single, definitive resource that podiatry professionals can rely upon to access important clinical knowledge on new therapies and treatments on a broad spectrum of topics, and enjoy a highly specialized content experience,” said David DePinho, President, HMP Global. “Healthcare professionals in the podiatry field will benefit from this comprehensive resource to receive ongoing professional development and provide the highest quality of patient care.”

 

PodiatrySource

 

HMP Global is also launching PodiatrySource, a one-stop resource with independent, clinically reviewed, and unbiased information to help clinicians make informed decisions about podiatry care products.

 

Powered by Podiatry Today, the award-winning, premier publication and online platform, PodiatrySource will reach buyers with the trusted information they need to act and make decisions about product selection and purchasing. It will provide 24/7 access to information on an interactive, user-friendly digital platform.

 

“The Podiatry Today audience is invested in providing patients optimal care and staying abreast of the latest product offerings across the field is part of how they achieve this goal,” said Jennifer Spector, DPM, FACFAS, Managing Editor of Podiatry Today, a trusted educational resource in podiatric medicine and surgery that provides engaging content to help clinicians improve patient care. “Creating PodiatrySource is a natural synergy of the education provided by Podiatry Today, with robust information about innovations provided by companies in the podiatric space.”

 

PodiatrySource currently highlights products focused on the office-based practitioner, and future updates will include more products and companies to best serve the full foot and ankle medical and surgical community, Spector said. PodiatrySource is open access with no subscription required for use. Industry contacts may submit product information through the website, and enhanced opportunities are available.

 

“PodiatrySource is designed to quickly become podiatry’s most relied upon tool to navigate the many options for products and services available to healthcare professionals in the podiatry community,” DePinho said. “It offers credible, trusted, non-biased clinically reviewed content that clinicians can use during the decision-making and purchasing processes.”

 

The new PodiatrySource resource guide is modeled after the highly successful WoundSource product reference guide. First published in 1998, WoundSource now includes more than 1,700 products manufactured by more than 200 wound care companies. Its digital companion, woundsource.com, includes product lists and reviews as well as articles, blogs by industry thought leaders, white papers, and other educational resources for wound care professionals.

 

For more information about PodiatrySource and the Podiatry Learning Network, visit hmpgloballearningnetwork.com/site/podiatrynet.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

 

Media Contact

Sandi Beason, APR, HMP Global, (601) 573-1737, pr@hmpglobal.com

 

SOURCE HMP Global

Wounds UK are pleased to announce the call for abstracts for the 2022 Wounds UK Annual Conference, held at the Harrogate Convention Centre, which will be held on 7-9 November 2022 at the Harrogate International Centre.

To submit your abstract use the following link: www.surveymonkey.co.uk/r/WUKH22Abstract

Poster presentations will be presented on electronic poster displays only, no hard copy posters will be on display.

Entries for the e-poster exhibition require you to submit an abstract. Every entry received will automatically be considered for the Wounds UK Award for Excellence 2022.

All abstracts will be reviewed by our judging panel, who will be looking to accept submissions that display high levels of innovation, relevance to current and/or best practice and provide high-quality research/evidence.

Award
The winner of the Wounds UK Award for Excellence will receive a free 3-day delegate pass with entrance to the gala dinner.

… read more

NANCY MORGAN

 

Every wound-care clinician treats diabetic patients regardless of your care point. In this course, Nancy will help you evaluate the wound, identify the best plan of treatment and steer you away from the potential setbacks for better healing rates and overall patient outcomes.

Objectives:

• Participant will identify the different types of Diabetes and Pre-diabetes and their effects on patients.
• Participant will identify skin conditions prone to patients with Diabetes.
• Participant will learn treatment options for Diabetic Foot Ulcers (DFU).
• Participant will discuss the high incidence of infections on patients with Diabetes and the importance of prevention.

… read more

Clinical and operational innovations better predict non-healing wounds and missed appointments

 

Further expanding its analytics capabilities and leadership position within the wound care marketplace, Net Health, a provider of specialty electronic health systems and advanced healthcare analytics, today announced the addition of two new predictive analytics resources to improve clinical and operational outcomes for wound care providers … The new Pressure Injury Deterioration Risk Indicator is built into Tissue Analytics, Net Health’s AI-powered wound imaging and analysis solution, which was recently granted breakthrough device status by the Food and Drug Administration (FDA). The Missed Visit Prediction Indicator is available in Net Health® Wound Care, one of the nation’s most widely used electronic health record (EHR) platforms for wound care. Both features are embedded in automated workflow processes and alert providers when risk is detected, enabling providers to intervene in real-time … read more

The Off-Loading Devices Market is expected to grow manifold in the upcoming period. With technological advancements like ML and AI being incorporated in abundance, the healthcare vertical is likely to reach the top pedestal in the years to come. There are Bluetooth-operated health monitors, which let doctors receive precise information, that too, from time to time … The unloading device is used to reduce physical stress on the ulcerative callus of diabetic patients, which is caused by poor circulation, lack of sensation in the foot, foot deformity or trauma. … These devices are designed to eliminate abnormal pressure points and promote healing … read more

New data has been published today (July 7) evidencing findings that could lead to better treatment for people with lethal lung infections and infected diabetic foot ulcers caused by antimicrobial resistant (AMR) bacteria … Clinical stage biotechnology company, Destiny Pharma plc., focused on the development of novel products to prevent life-threatening infections, revealed the publication of the new data on XF-73 with Cardiff University in Frontiers in Cellular and Infection Microbiology a peer-reviewed publication … read more

Regenative Labs CEO predicts this will have significant implications to advance multiple fields.

 

PENSACOLA, Fla., July 8, 2022 /PRNewswire/ — Regenative Labs, a leading FDA-registered and HTC/P manufacturer, confirms that the Institutional Review Board (IRB) of the Institute of Regenerative and Cellular Medicine (IRCM), an independent body which facilitates and validates regenerative and cellular medicine through collaborative and translational research, has approved its protocol for observational data of homologous use applications for Regenative’s products.

 

In noting receipt of the IRCM IRB letter, CEO Tyler Barrett observed that this is a key step in facilitating other studies for use of Regenative’s products. “We believe this will allow clinicians to explore new homologous use applications and make it easy to follow their patient outcomes,” he said, adding, “We are committed to advancing this field of research.”

 

The IRB letter confirms a key classification, known as 361, allowing Regenative to further studies for the use of its products.

 

“We are excited that this will allow us and our partner physicians to look for new uses,” said Barrett, pointing out that connective tissue is found throughout the body and that while the current use is heavily concentrated in addressing defects in the knee and specialties like orthopedics, Regenative has received queries and reports from specialties like podiatry and urology for cases of wound care and urinary incontinence.

 

In confirming receipt of the IRB’s letter, Regenative Labs confirmed their continued adherence to applicable state, local and federal regulations and requirements. They also look forward to a strong relationship with regulators.

 

The specific observational data collection approved is through MedngineTM of homologous use applications using ProTextTM, CryoTextTM,SecreTextTM, CoreTextTM and AmnioText.

 

Protocol number: RL-ME-002

 

IRB approval number: IRCM-2022-311

 

About Regenative Labs : Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with the daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at: https://regenativelabs.com.

 

SOURCE Regenative Labs

This article was originally published here

ActiGraft is an FDA-cleared wound care solution that enables health care providers to produce—in real time—in vitro blood clots from a patient’s whole blood. Once applied, the blood clot tissue serves as a protective covering and supports wound healing processes that naturally occur in the body. Testimonial: “I endorse ActiGraft as it uses the body’s own healing cascade to help initiate the wound healing process and has a unique role as a topical dressing in the wound care space.” —Dr. Bryan Doner, DO, D&P Medical Group … read more

Sarah Gardner and Sweta Rai

 

This session will help you understand the diversity and complexity of leg ulcers and also the management of unusual causes of leg ulcers. She aims to expand your knowledge base on different presentations of leg ulcers and will talk about evidence based management and newer techniques of leg ulcer management.

Dr Rai has an interactive and inclusive style of speaking and therefore questions and discussion will be very welcome during and after her talk … read more

Vegan diets have gained a lot of popularity around the world, mostly in America. About 6% of Americans claim that they are vegans. That is a 600% increase in veganism from 2017 to 2021. There are many reasons that people nowadays are adopting a vegan diet and it includes health and ethical reasons. One of the health reasons that this review refers to is type 2 diabetes. There have been previous studies of what a vegan diet has on the health and the prevention of metabolic syndrome. There have been studies that showed that the risk of cancer can be reduced on a vegan diet, but is still under debate that this is the main reason for it. The review aimed to show studies between vegan diets and see if there is a reduction in risk for type 2 diabetes … read more

Biofilm: A complex microbial community containing bacteria and fungi. The microorganisms synthesize and secrete a protective matrix that attaches the biofilm firmly to a living or non-living surface. The biofilm contributes to underlying wound infection, chronic inflammation, and delay in healing, and it is present in 80% to 90% of chronic wounds and 6% of acute wounds.

Epibole: Rolled or curled-under closed wound edges. These rolled edges are thickened epidermis that may be callused, dry, scaly, and/or hyperkeratotic. When epibole is present in a wound, it signals to the body that the wound has healed, even though the wound remains open. Epibole must be resolved to allow the wound to close … read more

Jennifer Spector, DPM, FACFAS

 

Each year, Podiatry Today hears from leaders in the world of foot and ankle medicine and surgery about important developments and significant strides being made in the field. Here is this year’s slate of the Top 10 Innovations in Podiatry (in no particular order) that could have an impact on your patients and practice … Pedilay med (Pedilay Care) is a ready-to-use secondary foot bandage that supports foot and ankle dressings associated with multiple conditions. The company explains that the bandage could save precious care time, as one can take it on and off in a swift and gentle fashion. The bandage, made up of a biocompatible, low-friction fleece material, has thin seams and can help protect the skin … read more

In a recent article published by GHP (Global Health & Pharma), Kent Imaging presents SnapshotNIR, their portable and lightweight near-infrared imaging device that is replacing some outdated and cumbersome technologies of the past, pioneering the future of effective wound care solutions. Through case studies and customer stories, clinicians share their hands-on experience with SnapshotNIR and how they are providing a greater standard of care to patients with this innovative technology … read more

FEATURED PRESENTERS: Mark Portou and Amelia Swift

 

What makes a wound complicated? Any non-healing wound can be described as complicated, but some are more complicated than others! Complicated wounds are usually found on patients with complex medical problems. Often complicated wound aetiology is multifactorial, but outcomes are significantly worse with underlying vascular disease. Medical optimisation and risk factor modification is required to treat the rest of the individual too … read more

TORONTO, July 7, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has been selected for a “Top Innovation in Wound Care 2022″ Award from Wound Management & Prevention (WMP) Journal for its MolecuLightDX™ device.

 

WMP provides news and information for professionals in wound care, ostomy care, incontinence care, and related skin and nutritional issues, and features ground-breaking research, peer-reviewed articles, and clinical discussions on topics relevant to the field. WMP and the Wound Care Learning Network are published by HMP Global, an omnichannel leader in healthcare content, events, and education.

 

MolecuLightDX was selected as a winner this year for its novel utility to provide a point-of-care tool to clinicians worldwide that enables the detection of elevated bacterial burden in wounds. Based on its extensive body of evidence and interviews with clinicians using it, the MolecuLight device is changing the standard of care in wound care.

 

“Wound Management & Prevention is dedicated to featuring the top innovations in wound care,” said Christiane Odyniec, Managing Editor. “Each July, the WMP Editorial Board nominates the newest innovations in the field of wound care, with the goal of sharing information to improve patient care. MolecuLightDX was nominated by our board for its innovation and practical applications, and we are pleased to recognize MolecuLight Inc. in this way.”

 

As part of WoundCon Summer 2022’s Technology Innovation Theatre, WMP will be hosting a webinar on “Wound Management & Prevention’s Top Innovations in Products & Care of 2022” on Thursday, July 14th at 1:30 PM EST. Five of the winning products will be featured, including the MolecuLightDX.
In this webinar, Dr. Charles A. Andersen, Medical Director of the Wound Care Clinic and Limb Salvage Program at Madigan Army Medical Center in Tacoma, WA will be speaking on his experience with MolecuLight and how it is changing his clinical practice. “Using MolecuLight has revolutionized our wound care practice and now allows us to provide proactive wound care,” says Dr. Andersen. “It’s a game-changer.”

 

Registration for the webinar is accessible here.

 

The MolecuLight i:X and DX devices are supported by a broad body of clinical evidence showing how they help to inform and improve clinical decision-making in wound care. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

• Image (Badge for a “Top Innovation in Wound Care 2022” Award from Wound Management & Prevention (WMP) Journal): Download
• Image (MolecuLightDX point-of-care device for imaging elevated bacterial loads in wounds and for performing stickerless digital wound measurement): Download  

 

SOURCE MolecuLight

Christopher Barrett, DPM, Dot Weir, RN, CWON, CWS

 

Provided by HMP Education, an HMP Global Company.

 

For questions regarding this educational activity, please call 609-371-1137 or email accreditation@hmpglobal.com.

 

INTENDED LEARNERS
This activity is designed for physicians, nurses, nurse practitioners, physician assistants and podiatrists across all practice settings involved in the prevention, treatment, and management of patients with wounds.

 

LEARNING OBJECTIVES
After participating in this activity, learners should be better able to:

Examine the efficacy and usability of disposable mechanically powered negative pressure wound therapy
Review best practices for using dNPWT in a variety of wound types
Explore illustrative case studies using dNPWT in a variety of wound types

… read more

Robert G Smith, DPM, MSc, RPh, CPRS

 

This Week’s Topic: Diabetic Foot Ulcer in Complex Patient

This week’s 5MinClinChallenge contributed by Robert G. Smith DPM MSc RPh FNAP, focuses on a complex diabetic ulcer patient involving alcohol and nicotine abuse, complaining of painful neuropathy. See if you agree with Dr Smith’s approach to this difficult case … read more

Terry Treadwell

 

This past weekend I was invited to be part of a group of wound care practitioners from the United States, Europe, Australia, and South Africa to design a manuscript to assist health care practitioners from around the world treat hard-to-heal wounds. At the meeting, cases were presented, and treatments were discussed, and it dawned on me that everything we were discussing was information that had been discussed many times before. It seems that no matter where in the world one treats wounds, the problems are the same and solving old problems is a major issue. As one who has had the privilege to teach and write about wound treatment in Sub-Saharan Africa, for me, the old topics became new again … read more

… read more

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) — About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and oversight of regenerative medicine products. The goal was to make sure these therapies – which are growing rapidly in numbers – are safe and effective for consumers, while also providing a framework to encourage innovation … The changing regulatory landscape provided the impetus for Merakris Therapeutics to immediately engage with the FDA on its technology and the steps required to meet the new requirements, according to the Research-Triangle headquartered company’s CEO, Chris Broderick. Merakris was one of the first companies in its industry to do so … read more

Medtech innovation briefing [MIB296]Published: 10 May 2022

The technology described in this briefing is Granulox … Granulox is a topical sterile haemoglobin spray for managing chronic non-healing wounds … The innovative aspects are that, unlike other oxygen delivery technologies, it is designed to allow oxygen to diffuse through wound exudate … It can also be used in various settings without costly consumables, electrical power or full or partial body coverage in a chamber … The intended place in therapy would be alongside standard care for people with chronic non-healing wounds … The main points from the evidence summarised in this briefing are from 8 studies (1 meta-analysis, 2 randomised controlled trials and 5 observational studies) including a total of 530 people … Seven studies were based in the UK and are generalisable to the NHS … The evidence suggests that Granulox may improve the management of chronic non-healing wounds … Key uncertainties around the evidence are that sample sizes are small, and most studies were not randomised and had a short follow-up period … read more

to Identify Regions Containing Elevated Load and More Bacterial Species

 

New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect
Clinically Significant Bacteria that Impedes Wound Healing

 

TORONTO, June 29, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion to its FDA 510(k) clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads (>104 CFU/g) in wounds. The expanded labelling also includes the device’s ability to identify areas of wounds containing more bacterial species, including key target pathogens of interest to the CDC that are major causes of antimicrobial resistance1. Detectable species include gram-negative and gram-positive species, aerobes and anaerobes. This expanded labeling is based on a detailed retrospective statistical analysis of over 350 patients.

 

 

“We are thrilled with the FDA’s new clearance for MolecuLight’ ability to determine the location of elevated bacterial loads in wounds, in addition to the ability to identify regions with more bacterial species of interest”, says Anil Amlani, MolecuLight’s CEO. “Clinicians worldwide are using the MolecuLight device to visualize regions with clinically significant bacterial loads and more species of concern. With point-of-care information on bacterial load and its locations through use of a MolecuLight device, clinicians can act immediately to tailor their cleaning, debridement, antimicrobial strategies and treatments accordingly.”

 

This video (courtesy of Rose Raizman) illustrates the importance of visualizing the location of elevated bacterial load in a wound. In this scenario, the clinician is using MolecuLight i:X to inform their decision-making and target their wound hygiene to the areas of red fluorescence. Regions of red, indicating that the wound contains clinically significant (>104 CFU/g) levels of bacterial burden, are clearly visible on the patient’s diabetic foot ulcer (see image).

 

In addition, the FDA has also recognized MolecuLight’s ability to visualize regions containing troublesome bacterial species at the point-of-care. The MolecuLight device can be used to enable fluorescence-guided tissue biopsies to these regions to detect a higher number of pathogens of interest (defined by the CDC as increasing risk to develop antibiotic resistance) compared to standard-of-care-guided biopsies. The CDC has identified antibiotic resistance as “one of the greatest global public health challenges of our time”1. Strategies to combat antibiotic resistance include containing emerging threats through early detection and aggressive response and improving appropriate antibiotic use through antimicrobial stewardship programs. The expanded use of diagnostic tools, like MolecuLight, to improve accuracy and speed of pathogen detection has been called out to help improve appropriate antibiotic selection and reduce unnecessary antibiotic use1.

 

MolecuLight was the first to receive FDA de novo clearance for its MolecuLight i:X imaging platform and has subsequently received three additional FDA 510(k) clearances for the device.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

www.moleculight.com

 

Image: Download at: https://moleculight.box.com/s/ax8758gz0f8amouhcjjvs4xzkfa9vofo
Video: https://youtu.be/HKOCGBlIQj4

 

SOURCE MolecuLight

 

 

In a study of over 7,000 chronic limb-threatening ischaemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention rates; survival, however, was higher among Black patients and similar between Hispanic and White patients. Aderike Anjorin (Duke University Medical Center, Durham, USA) delivered these findings at this year’s Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM 2022; 15–18 June, Boston, USA) … Framing the research, Anjorin stated that Black and Hispanic patients have higher rates of CLTI and suffer worse outcomes after lower extremity bypass compared with White patients. The underlying reasons for these disparities are unclear, she said, specifying that data on long-term outcomes are limited. In order to address this gap in the literature, Anjorin and colleagues examined differences in three-year outcomes after open infrainguinal … read more

MEMPHIS, Tenn.–(BUSINESS WIRE)–FedEx Corp. (NYSE: FDX) and Direct Relief continue to support those affected by the conflict in Ukraine. On Sunday, June 26, FedEx Express safely delivered 52 tons of critical medical aid to Poland from the United States via a FedEx humanitarian relief flight. This follows FedEx and Direct Relief’s first charter flight of aid for Ukrainian refugees in March and is the latest in a continuous series of shipments from Direct Relief … Aid aboard the FedEx Express Boeing 777 cargo aircraft included substantial quantities of emergency medicines and supplies, including health kits, trauma and wound care items, chronic disease and chemical exposure medications, and antibiotics. All items were provided at the request of, and approved by, Ukraine’s Ministry of Health and local Ukrainian organizations. Direct Relief team members were on site for the offload and the aid will be distributed to health facilities within Ukraine … read more

Hayley Ryan and Helen Jentz

 

Wounds Australia celebrated its 28th anniversary this year. Like many peak national organisations, over the course of our history, Wounds Australia has had to evolve and adapt to the ever-changing health and social landscapes in which we operate. Central to our ongoing success as a peak body is the commitment of our members, the health professionals who have chosen to dedicate themselves to the highly specialised and complex area of wound prevention, diagnosis, treatment, care, healing and research … As an organisation that is focussed on effective, real and sustainable systemic change that will result in significant improvements in the lives of Australians living with wounds, we are also dedicated to broadening the ways in which we, as the peak national body for wound prevention, treatment and healing, can support and assist those living with wounds and the families who love and care for them … read more

Allyson Y. Schwartz, Jon Bloom, M.D.

 

Lower limb amputations are devastating for people living with diabetes, particularly for Black Americans facing poor access to comprehensive care. A coordinated, data-driven national prevention strategy is the only way to curb this growing epidemic for all at-risk populations … When President Joe Biden rightly called out the unsustainably high price of insulin in his 2022 State of the Union Address, he wasn’t saying anything new for most industry observers. Rising insulin prices have been the subject of national conversation for years, and the push for a reasonable cap on out-of-pocket expenses has been a perennial rallying point among providers and patient advocates … Capping insulin costs is an important step, but it is just a start if we are going to stop people living with early diabetes from experiencing a worsening of their condition … The statistics and the people behind those numbers demand greater attention, smarter care, and a life free of the serious consequences of uncontrolled, complex diabetes … Consider these numbers. More than 37 million people are living with diabetes in the United States — and a further 96 million individuals have prediabetes … read more

Hemostatic Solutions for Trauma Injuries Presents Opportunities – ResearchAndMarkets.com

The “Growth Opportunities in Military Medical Device Technologies” report has been added to ResearchAndMarkets.com’s offering … Over the years, the healthcare industry has developed several unique technologies for emergency medical services and critical care. An important user of critical care healthcare products is the military or the defense forces. Advanced medical technologies have improved the care that is offered, and they also enable safer and quicker care for soldiers … Severe hemorrhages can result in hemodynamic instability, hypoxemia, multiple organ failure, or death. A key reason for patient fatality is blood loss due to trauma or injury on the battlefield. Typically, intravenous (systemic) or local (topical) hemostatic agents are used to control excessive bleeding … read more

Eli Cahan

 

Leafer Miller didn’t hear much after the doctor told him they had to “sacrifice the leg.” … Lying on the emergency room gurney, the self-proclaimed video game nerd and former athlete struggled to comprehend life without the leg that had propelled him on the track and to the turf for tackles on the soccer field … “It was always in the back of my mind as a worst-case scenario,” the 35-year-old Fresno, CA, native says. “But I wasn’t expecting that to be the case.”
… read more

Robin Lenz and Fahad Hussain

 

For the patient, the prevention of sores and injuries is better than treating them. Pressure-relieving mattresses may be essential for preventing pressure injuries (bed sores). These mattresses aid in relieving and redistributing pressure and can thereby cause a reduction of friction and shearing. Pressure-relieving mattresses provide support for the body and reduce the amount of force applied to a given area. Thus, for bedbound patients and patients who are unable to reposition themselves, these types of beds can be especially beneficial … read more

We (The Society of Tissue Viability) have over 100 resources, free for everyone to browse and read and share. These resources are suitable for a range of skin and wound care disciplines, roles, and educational purposes.

 

The university-level modules are aimed at supporting Continuing Professional Development and cover a range of topics from basic skin anatomy and physiology through to wound healing and dressing selection.

 

The five higher tier modules are fully endorsed by the Society of Tissue Viability.

 

You will need to sign up to the ActivHeal Academy to access these courses

 

Module 1: Anatomy & physiology of the skin
To understand how wounds heal, it is important to have a basic knowledge of the anatomy and physiology of the skin and the structures that lie within it. ESTIMATED TIME REQUIRED: 60 MINUTES

 

Module 2: Wound healing
After an injury to the body has occurred, healing of the wound takes place in order to restore the intact barrier provided by the skin. ESTIMATED TIME REQUIRED: 60 MINUTES

 

Module 3: Patient and wound assessment
This module looks at the important criteria to consider including wound assessment tools to encourage you to critically analyse established wound assessment tools used within the clinical environment. ESTIMATED TIME REQUIRED: 90 MINUTES

 

Module 4: Wound classification and wound management
This module will look at different wound types and the most frequently used methods by which they are staged and managed. This is meant as a guide and may compel you to look at the research behind your current practice.

 

Module 5: Dressing selection
As the number of wound care dressings available on the market continues to grow this course looks to ensure that the correct treatment is carried out. ESTIMATED TIME REQUIRED: 90 MINUTES

 

https://academy.activheal.com/

Special Report on MASD written by Elizabeth Faust, MSN, CRNP, CSWS, CWOCN-AP, MAPWCA; Siobhan McCoulough, CNS; and Patricia Idensohn, CNS

 

Moisture-associated Skin Damage (MASD), as the name suggests, occurs when exposure to a moisture source results in a breakdown of skin integrity. MASD is an umbrella term for a number of conditions including incontinence-associated dermatitis, peri-stomal skin damage, peri-wound skin damage and intertrigo. These conditions can impact greatly on patients so protecting the skin from damage and promoting wound healing are integral parts of skin and wound care. This area contains a variety of different resources to help aid understanding of MASD, so please sign up to our events, and explore to learn more!
… read more

Oleg Teleten, MS, RN, CWCN
Tatyana S. Polyak, MD
Jessica Espinoza, OTS
Andrew I. Li
Ariel J. Rodgers, MD
Holly Kirkland-Kyhn, PhD, FNP, GNP, CWCN, FAANP

 

Pressure ulcers/injuries (PU/Is) are still highly prevalent in the acute care setting. According to the Joint Commission Center for Transforming Healthcare (2021), more than 2.5 million patients in US acute care facilities are estimated to have PU/Is each year, and 60,000 die of their associated complications.1 PU/I development has many contributing factors, including prolonged pressure over bony prominence due to inactivity/immobility, shearing between skin surface and mattress/seating surface,2 poor perfusion,3 tissue ischemia, and prolonged high surface interface pressure.4-6 Incidence of PU/Is has been shown to be associated with increased disease burden, financial burden, and increased in-hospital mortality rates … read more

… read more

In this video, Paul Kim, DPM, MS, FACFAS, discusses the clinical implications and considerations of using negative pressure wound therapy with instillation in wound care.

Paul Kim, DPM, MS, FACFAS, is a professor in the Department of Plastic Surgery and Orthopedic Surgery and is the Medical Director of the Wound Program at the University of Texas Southwestern in Dallas, Texas. For more content, visit the Negative Pressure Wound Therapy topic center … watch video

This table illustrates common wound care services and procedures performed at hospital outpatient settings, and refers to Centers for Medicare & Medicaid Services (CMS) facility fees. For Medicare Physician Fee Schedule, see topic “HCPCS/CPT Codes Commonly Utilized in Wound Care and HBOT”.

Instructions for the interactive Tool below: 1. Select number of entries (rows) to be displayed on the table. 2. Use the “Search” field to find a specific code or description. For educational purposes only. Your hospital chargemaster, Medicare Administrative Contractor (MAC) and Coverage Determinations should serve as the definite source of billing guidelines … read more

Patients with systemic sclerosis who demonstrate digital ulcers use “significantly more” health care resources annually than patients without digital ulcers, according to data published in Arthritis Care and Research … “[Digital ulcers (DUs)] are slow to heal, specially if there is calcinosis, and can be complicated by soft tissue infections, wet and dry necrosis, eschar, underlying tissue exposure, gangrene, osteomyelitis, and amputation,” Tatiana Nevskaya, MD, PhD, of the Schulich School of Medicine and Dentistry, in Ontario, and colleagues wrote … read more

By signing up to LeaRn On Demand today you will have access to:

• E-learning modules covering wound care, compression therapy and much more, that can contribute to the non-participatory hours of CPD required for revalidation
• L&R brand videos, resources and information
• A new community where you can connect with others in your profession
• A platform to ask questions at any time!

… read more

Many people have now embraced the plant-based meat movement. Plants high in protein, such as soybeans, are common ingredients, but it’s been unclear how much of the nutrient makes it into human cells. In ACS’ Journal of Agricultural and Food Chemistry, researchers report that proteins in a model plant-based substitute were not as accessible to cells as those from meat. The team says this knowledge could eventually be used to develop more healthful products … read more

During (National) Diabetes Awareness Week from 13 to 19 June 2022, Neuropad® a 10-minute pain-free screening test for the early detection of diabetic foot syndrome, a condition which can lead to serious complications such as foot ulceration, and amputation is raising awareness about this condition. Foot complications are the most feared of all the complications of diabetes, however, alarmingly, 30% of people with diabetes are unaware that foot complications are common and serious if detected late. Another sobering statistic is that the five-year mortality post amputation is worse than most common cancers and much higher than breast cancer … Nerve damage to the feet is a common complication of diabetes, but often goes unnoticed. Neuropad helps solve this problem with a simple colour change test, that provides an early warning sign … read more

Chronic wounds affect nearly 15% of Medicare patients (8.2 million people) and may cost as much as $96.8 billion per year. The most common are not venous or diabetic, even though they are the most often studied in prospective trials. The most common chronic wounds are surgical incisions that dehisce and the “wounds with no name” due to the patients’ underlying medical conditions. That is because wounds are not a disease – they are a symptom. The US Wound Registry (USWR), a 501 (c)(3) non-profit organization, has been a patient registry since 2005. Since 2014, the USWR has been recognized by the Centers for Medicare and Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) that collects medical and/ or clinical data for the purpose of improving the quality of patient care. While we understand that randomized, controlled trials are needed to demonstrate efficacy in a perfect world, real-world patients have an average of 6 serious co-morbid conditions and take 10 medications. These complicated patients are invariably excluded from clinical research studies, which makes it impossible to know what treatments work best … read more

The agenda has not yet been confirmed for this meeting. Please check again at a later date for more information, or call on 020 3735 8244.
… read more

We have recently been informed by our long-term funder, the NIHR, that funding for all the review groups they currently fund will terminate on 31 March 2023, and at that point Cochrane Wounds will also cease to exist. This means that we have to make difficult decisions about which reviews we will support between now and then, as our resources are limited in amount and duration.

Unfortunately, we will not be able to accept new titles and we will only proceed with high priority, high quality reviews that meet deadlines and can be produced relatively independently by author teams in an efficient way … read more

Why Do Chronic Wounds Contain Biofilm?
The process of wound healing ideally progresses from inflammation to epithelialization and, finally, remodeling. If at any point bacterial (or fungal) colonization becomes prominent, the process of wound healing is disrupted. The creation of biofilm is a microbial defense mechanism that stalls the trajectory of healthy wound healing and can contribute to the development of a chronic wound. It is estimated that 90% of chronic wounds and 6% of acute wounds contain biofilms generated by microbes.1,2 Epidemiologically, chronic wounds impact 2% of the entire US population.2 Because of this large impact, knowledge of proper wound healing and use of clinical tools to assist the wound healing process are essential … read more

Keynote Speakers: Sarah Gardner, Kristina Stiles, Paul Hardy

 

Free service specific/specialist days promote the best practices in skin health and wound healing … Caring for children with a chronic illness or disability can pose many challenges to healthcare professionals. Frequently this includes the risks associated with maintaining skin integrity and wound healing when faced with complex factors that can impact on patient outcomes … This advanced study day will explore some of the factors that need to be considered when assessing children with complex skin and wound care needs and will also provide insight into managing specific conditions such as pilonidal sinus, pressure ulceration and leg ulceration … read more

Chronic and nonhealing wounds are a worldwide issue and are becoming more difficult to treat. In the United States alone, according to Medicare, over 8 million Americans have chronic wounds that cost the national health care system between $18.1 and $96.8 billion per year.1 If standard treatment does not adequately heal a wound, additional methods of wound care treatment may be required, and the underlying disorder must be examined to determine the need for advanced wound care modalities. Advanced wound care therapies are interventions that are used after standard wound care has failed … read more

Module 1: The Skin

 

This forms part of a series of modules you can access to develop your knowledge and understanding of wound care. This module is endorsed by The Society of Tissue Viability

 

By the end of this module, you will be able to:

• Name the different layers of the skin
• Recognise how the different layers interact with each other
• Recall the functions of the skin
• Recognise the effects of ageing on the skin
• Complete the 15 minute version of this module to download a training certificate which can go towards CPD revalidation: https://youtu.be/BcImfXNwwK4

 

This video is intended for health care professionals. It is offered for informational and educational purposes only and is not intended as medical advice. Viewer discretion is advised.

 

… read more

Validation study to assess up to 200 adult subjects with participation from leading U.S. principal investigators.

 

DALLAS, June 14, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the start of its clinical validation study to support the development of its Diabetic Foot Ulcer (“DFU”) application for the DeepView® Wound Imaging System. The proprietary technology combines multi-spectral imaging and Artificial Intelligence (AI) to provide clinicians with an immediate healing assessment for DFU, which enables clinicians to provide a more accurate and timely diagnosis for therapeutic intervention.

 

The study will collect data from up to 200 adult subjects across seven potential clinical sites to further develop DeepView®’s AI algorithm. Patient enrollment for the validation study began this month and is expected to complete in November 2022.

 

Building upon promising results from the clinical training study, where the current diagnostic accuracy is 81%, the data collected from the validation study will be used to bolster the Company’s existing clinical database of DFU images and physiologic information to train and improve the DeepView® AI algorithm. Additionally, the validation study will collect data from a broader population set of up to 200 subjects to increase geographic and ethnic variability. Importantly, data collected will support the Company as it prepares FDA and CE mark submissions for DeepView®’s DFU indication, planned in 2023.

 

Participating investigators include: Dr. Alisha Oropallo, MD, Director of Comprehensive Wound Healing Center at Northwell Health; Dr. Brock Liden, DPM, Podiatry Specialist at Circleville Foot & Ankle Center, LLC; and Dr. Babajide Ogunllana, DPM, West Houston Foot and Ankle Center. Additional clinical sites are being evaluated and will be incorporated into the validation study in the near future.

 

Dr. Alisha Oropallo, M.D., FACS, FSVS, Director of Comprehensive Wound Healing Center at Northwell Health and National Principal Investigator for the study, commented: “For patients with diabetes, foot ulcers can impact their quality of life and lead to complicated infections and potential amputation. I look forward to participating in this study as DeepView® has significant potential to improve the current standard of care, resulting in faster application of advanced therapy, better wound healing and reduced overall hospital visits and utilization.”

 

Mary Regan, Ph.D., VP of Clinical Affairs at Spectral MD, said: “We are very pleased to have initiated the Clinical Validation Study, the next critical step towards the completion of development for the DFU application for DeepView® Wound Imaging System. To obtain robust clinical data, the Spectral MD team has selected leading wound care providers to advance and develop our DeepView® Wound Imaging technology. I look forward to working with all participating clinical sites to ensure high-quality data and clinical engagement.”

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView®Wound Imaging System.

 

www.spectralmd.com

 

info@spectralmd.com

 

This article was originally published here

The Alliance submitted detailed comments and recommendations to Novitas on its Draft LCD on Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (DL35041) and accompanying draft Local Coverage Article (DA54117). In April oral comments submitted at Novitas’ public meeting, the Alliance had flagged – among other issues – provisions in the policy not supported by scientific evidence, as well as conficting and/or clinically incorrect policy language. In written comments, the Alliance submitted a chart (attachment A) detailing the specific provisions/policy language it flagged as problematic, the issues of concern underlying to those provisions, specific language changes to address the concern, and the clinical evidence supporting these recommendations. The chart was accompanied by additional attachments, including HCPCS and ICD-10 Codes to be added and a red-lined mark-up of suggested line edits (attachments B-E). See comments and attachments below … read more

Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces it will participate to the scientific symposium “Phage therapy: French experience”, which will be held on June 15, 2022 from 5:15 pm to 6:30 pm in the amphitheater A of the Palais des Congrès in Bordeaux, as part of the 23rd National Days of Infectiology (NDI).

 

The symposium, moderated by Dr. F.-A. Dauchy from the Bordeaux University Hospital, will host the following presentations:

 

Phagotherapy and IOA. Compassionate cases and clinical studies including PhagoDAIR: Pr. T. Ferry (Lyon)
Phage therapy and Infections of the Diabetic Foot Ulcer. State of knowledge. PhagoPied: Pr. A. Sotto (Nîmes)
Phage therapy and pulmonary infections. Preclinical results. Planned clinical studies: Dr. A. Bleibtreu (Paris)
Pascal Birman, Medical Director of Pherecydes Pharma, comments: “Antibiotic resistance is a major public health issue and is a central theme at this 23rd edition of the NDI. This symposium is an opportunity to highlight the interest of phage therapy through several clinical studies that will be conducted in different indications and through compassionate treatments already performed with our phages. Pherecydes Pharma and its partners are doing their utmost to ensure that these studies provide useful answers to improve the treatment of patients suffering from antibiotic resistant infections.”

 

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

 

For more information, www.pherecydes-pharma.com

 

Contacts
Pherecydes Pharma
Thibaut du Fayet
Deputy CEO
investors@pherecydes-pharma.com

 

NewCap
Dusan Oresansky
Investor Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 92

 

NewCap
Arthur Rouillé
Media Relations
pherecydes@newcap.eu
T.: +33 1 44 71 00 15

 

This article was originally published here

Once a pressure injury has appeared, you need to take immediate action. Contact your health professional for all pressure injuries regardless of the stage. You may be referred to a wound care specialist to help heal your wound. Do not be embarrassed as you know pressure injuries develop for a variety of reasons, many of which do NOT include lack of care on your part. A pressure injury usually occurs due to combinations of reasons that can include self-care issues but also metabolic reasons … You need to be evaluated for treatment. If the wound is open, a treatment plan will be made for you to follow. If you see a change in pigmentation without an opening in the skin that you have dealt with previously, you may already know your plan. You will need to work with your healthcare professional if an area is repeating pressure injuries … read more

According to new research by investigators at the Mayo Clinic and Washington State University, e-bandages could be an effective alternative to antibiotics for managing wound infections. The findings are presented at ASM Microbe 2022, the annual meeting of the American Society for Microbiology … In a recent study conducted in mice, novel hydrogen peroxide producing bandages with electrical/chemical properties (electro-chemical bandages or e-bandages), under the control of wearable voltage devices, reduced methicillin-resistant Staphylococcus aureus (MRSA) biofilm bacteria present in the wound by 99 percent after 2 days of treatment … read more

13-Jun-2022 8:05 AM EDT, by Orpyx Medical Technologies Inc.

 

Newswise — CALGARY, AB, June 13, 2022 /PRNewswire/ — Orpyx® Medical Technologies Inc. (Orpyx), a digital health company focused on extending the health span of patients with diabetes, announced the launch of the Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services. This remote monitoring program drives engagement and extends mobility for people living with diabetes by transforming patient care through real-world patient data, analytics, and coaching.

“The launch of Orpyx SI Flex is our next step in enabling Diabetes Healthspan Extension™,” stated Dr. Breanne Everett, CEO and co-founder of Orpyx. “In North America, one-third of people are living with diabetes or pre-diabetes which often requires juggling an overwhelming number of actions, measurements, and appointments. By taking a holistic approach through a digital care platform we can dramatically improve upon the current standard of care. We are starting with foot care through robust data generation via our sensory insoles, and supporting patient engagement through RPM and coaching.”

 

The Orpyx SI Flex Sensory Insole system is a wearable technology designed to help prevent plantar foot complications for at-risk patients with peripheral neuropathy. “It is like having a supercomputer on the bottom of each foot,” said Denis Brisson, Chief Operating Officer at Orpyx. “Plantar pressure is a leading cause of foot ulceration so by measuring sustained high pressure we can help eliminate the root cause of many of these wounds before they happen.”

 

Along with pressure, the system captures wear time to determine how compliant the patient is to their provider’s treatment plan, step count to help dose activity levels, and temperature the last line of defense to indicate when inflammation is present and tissue damage is occurring. The ultra-thin, prefabricated sensory insoles fit in most every-day footwear, making them practical and comfortable for a broad range of patients.

 

Orpyx is changing the conversation by initially focusing on preventing foot ulceration by generating the most robust set of real-world plantar data. Historically, the focus has been on how to treat patients’ foot ulcers after they have already formed, with disappointing results as 25% of people with diabetes will develop an ulcer during their lifetime. These ulcers have a detrimental impact on patients’ mobility often resulting in life-shortening events such as amputation which can cause a ripple effect of social isolation, mental health challenges, and in the most complex situations death. Most diabetic foot ulcers (DFUs) are preventable, so we are on a mission to help patients and providers achieve improved, sustainable outcomes.

 

“Healthcare systems cannot sustain the current clinical strain of managing the 34 million people with diabetes in the US and the resulting $176B in financial costs. One third of this cost is attributed to lower limb care which is why this is such important work,” continued Dan Hughes, Orpyx’s Chief Commercial Officer. “Orpyx SI Flex Sensory Insoles and our new RPM services were specifically developed to meet these challenges head-on. Our insoles will play a significant role in the diabetic care pathway enabling patients to take proactive steps to manage their diabetes while reducing the total cost of care for Commercial Payers and Integrated Delivery Networks across the United States. Ultimately, this technology drives alignment and better outcomes for patients, providers, payers, and physicians.”

 

Healthcare providers seeking additional information to help their patients prevent DFUs can learn more about the new Orpyx SI Flex Sensory Insoles at https://www.orpyx.com/orpyx-si-flex-sensory-insoles.

 

About Orpyx Medical Technologies Inc.

 

Founded in 2010, Orpyx® Medical Technologies Inc. (“Orpyx”) is a Calgary-based digital health company. We take a holistic approach to remote “anywhere” care, which includes the company’s proprietary, imperceptible sensory insole platform that detects pressure, temperature, gait, activity, and movement symmetry. Our comprehensive Orpyx SI® Sensory Insole system enables continuity of care between visits to provide optimal remote care for people living with diabetes or recovering from surgery. The patient’s data is uploaded to the Orpyx SI cloud-based dashboard, where accredited healthcare practitioners remotely monitor it. The remote monitoring team communicates directly with the patient between care visits to ensure ongoing continuity and quality of care.

 

Visit www.orpyx.com for more information.

Electrochemical bandages (e-bandages) that contain hydrogen peroxide could be an effective alternative to antibiotics when managing wound infections, according to a presentation at ASM Microbe 2022, the annual meeting of the American Society for Microbiology held in Washington, DC (abstract 2281) … Researchers from Mayo Clinic and Washington State University conducted experiments in mice. They created wounds on mice and infected them with methicillin-resistant Staphylococcus aureus (MRSA) to establish wound MRSA biofilms … read more

A prospective, randomized controlled trial

 

Chitang J. Joshi MD,Miguel Carabano MD,Laura C. Perez MD,Peter Ullrich,Abbas M. Hassan MD,Rou Wan MD,Jing Liu MD,Rachna Soriano DO,Robert D. Galiano MD, FACS

 

The Fluid Immersion Simulation system (FIS) has demonstrated good clinical applicability. This is the first study to compare surgical flap closure outcomes of FIS with an Air-Fluidized Bed (AFB), considered as standard of care. The success of closure after 14 days post-op was the primary endpoint. Secondary endpoints were incidences of complications in the first two weeks after surgery and the rate of acceptability of the device. 38 subjects were in the FIS group while 42 subjects were placed in the AFB group. Flap failure rate was similar between groups (14% vs 12%; P= 0.84). Complications, notably dehiscence and maceration, were significantly higher in the FIS group (40% vs 17%; P=0.0296). The addition of a microclimate regulation device … read more

Jarrod Shapiro, DPM, FACFAS, FACPM, FFPM, RCPS Glasg

 

Recently, I had the pleasure to take my first real vacation since the pandemic started. Three years is definitely long enough to wait for a fun trip! But being on vacation had me wondering if a short time off is actually beneficial? Do vacations improve health? Or are we fooling ourselves into thinking short breaks from work do anything to improve long-term health? Let’s see what the research tells us … read more

PLANO, Texas, June 6, 2022 /PRNewswire/ — Non-healing diabetic foot wounds are increasing in prevalence, and create a higher risk for infection, osteomyelitis and amputation. To facilitate appropriate wound healing processes, proper debridement of the wound bed is critical to remove non-viable tissue and bacterial biofilm. Traditional debridement methods involve the use of a sharp blade, a method that often results in the removal of healthy, viable tissue and pain for the patient. In contrast, the Swiss wound care company, Medaxis has developed the debritom+ to precisely clean acute and chronic wounds in a tissue-preserving manner. By using Micro Water Jet technology, the debritom+ removes the unhealthy tissue such as fibrin, necrosis, and biofilm efficiently while performing a precise mechanical cleaning and stimulation of the wound base to enhance granulation and healing.

 

Results from the interim analysis of a Multicenter Randomized Control Trial (NCT04564443) that has been accepted for presentation this week at the American Diabetes Association annual meeting in New Orleans, showed that weekly debridement using the debritom+ nearly doubled the rate of wound healing from 40% to 72% compared to the use of traditional methods. Also shown was a significant improvement in wound size reduction (87% versus 35%), while also reducing the frequency of infections and complications.

 

Study Chair, Professor David Armstrong DPM MD PhD of Keck School of Medicine of University of Southern California noted “The early data suggests great promise that better debridement tools can improve wound closure and decrease diabetic foot related complications and infections. This study supports that improved debridement methods, combined with good quality dressings and offloading, is beneficial and possibly synergistic to achieve wound healing in non-healing diabetic foot ulcers.”

 

“To initiate wound healing, a quality debridement is key to success. In contrast to traditional debridement methods that remove both the non-viable and healthy tissue, the debritom+ by Medaxis removes only the non-viable tissue while preserving the healthy tissue underneath. By creating microbleeding and providing the oxygenation to the wound that is necessary for starting the healing process, the debritom+ has now been proven to initiate healing in nearly twice as many wounds as with traditional methods with six-times fewer infections and complications” stated Dr. Mark Cregan, Managing Director of Medaxis USA.

 

Beat Moser, CEO of Medaxis said “These results validate the design philosophy of the Medaxis debritom+. The use of our patented Micro Water Jet Technology has now been proven to significantly improve wound healing outcomes. I have always believed that clean wounds heal better, and now we have the hard evidence.”

 

To view the study results, or for more information about the debritom+ by Medaxis, please see www.medaxis.us, email info@medaxis.us, or call (312) 483-6214

 

SOURCE Medaxis LLC

 

This article was originally published here

A skin biopsy is often used to diagnose skin cancer and other skin conditions … It involves the removal of a small amount of skin, which is examined under a microscope. Afterwards, you’ll need to look after the biopsy location to make sure it heals properly … Your dermatologist will treat the small wound from the skin biopsy during your visit,” said dermatologist Dr. Rajiv Nijhawan, an associate professor at UT Southwestern Medical Center in Dallas … read more

in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

 

Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)

 

BOZEMAN, Mont. and VANCOUVER, BC, June 7, 2022 /PRNewswire/ – Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infections”. The funding received will be used to support the conduct of an exploratory phase 2 proof of concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection with enrollment expected to begin in Q2 2022.

 

“We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. Further exploration of pravibismane’s safety and efficacy in overcoming biofilm-related DFI may potentially expand the clinical utility of topical pravibismane to treat combat wound infections in a variety of settings, including in the field and hospital.”

 

Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board commented on the importance of Microbion’s research. “Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among veterans. Microbion’s research into healing these wounds with the ultimate goal of preventing or delaying amputations can potentially improve the daily lives of these patients and return normal mobility,” Dr. Martinez stated.

 

Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa.

 

In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. Pravibismane also demonstrated a numeric reduction in ulcer-related amputation (2.6% in the pravibismane group vs 15.4% placebo).

 

DFIs are a major health concern in the Veterans Health Administration as DFUs are associated with a substantial mortality rate (five-year mortality rates are as high as 45% for neuropathic ulcers and 55% for ischemic ulcers1) and often require amputation to fully address the nidus of infection.2 Approximately 28.5 million adults in the US are diagnosed with diabetes, of whom 15 – 25% are at risk of developing a foot ulcer.3,4 More than half of diabetic foot ulcers become infected.5 DFIs remain the most frequent diabetic complication requiring hospitalization and are the most common precipitating event leading to lower extremity amputation.6 Furthermore, recent studies suggest that many DFIs are caused by bacteria in a biofilm mode.6 In 2018, there were ~8.25 million hospital discharges with diabetes reported, including 154,000 for a lower-extremity amputation.3 US Veterans Affairs estimates there were 20.3 million living Veterans in 2018.7 The overall prevalence of diabetes among US veterans is ~25%, which is higher than the US civilian population at ~9%.8

 

References:

1. Del Core MA, Ahn J, Lewis RB, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864
2. Sundararajan PP, Porter BM, Grant KA, et al. Foot infections in the Veterans Health Administration. The Foot and Ankle Online Journal. 2015;8(3):1. doi:10.3827/faoj.2015.0803.0001
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html, accessed June 6, 2022
4. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24(1):112–26. doi: 10.1111/wrr.12391
5. Armstrong, DG, Boulton, AJM, and Bus, SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75. doi: 10.1056/NEJMra1615439
6. Lipsky et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diab Metab Res Rev. 2020. e3280. doi: 10.1002/dmrr.3280
7. VETPop2018: A Brief Description. Web: https://www.va.gov/vetdata/docs/Demographics/New_Vetpop_Model/VP_18_A_Brief_Description.pdf, accessed June 6, 2022
8. Liu Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 2005–2014. Prev Chronic Dis. 2017;14:170230. doi: 10.5888/pcd14.170230

 

About Microbion
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Microbion Pharma Corp. is a wholly owned subsidiary of Microbion Corporation. For more information visit: www.microbioncorp.com.

 

About CUBRC
CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. For more information visit: www.cubrc.org.

 

Safe Harbor Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

US Government Funding Disclaimer
Efforts described herein were partially sponsored by the Government under Other Transactions Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

 

SOURCE Microbion Corporation

This article was originally published here

First time an EHR company has received Breakthrough Device Status

 

PITTSBURGH, June 2, 2022 /PRNewswire/ — Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The Company believes the FDA designation represents the first time an EHR company has been granted such designation.

 

Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is not granted solely on the severity of the device’s applicable condition. The submission must also meet one of the following criterion: the proposed device represents “breakthrough technology” as defined by the FDA; no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

 

Net Health’s Tissue Analytics Technology Pushes the Boundaries

“Finding ways to help our clients more quickly and accurately identify potentially life-threatening wounds and manage associated costs has been a priority for more than 20 years,” said Josh Pickus, CEO of Net Health. “The FDA designation highlights that Net Health is redefining EHRs as much more than simple documentation systems. Our intelligent AI-driven analytics solutions are pushing the boundaries of EHRs and helping change healthcare outcomes.”

 

Thu, June 2, 2022, 8:00 AM·3 min read
First time an EHR company has received Breakthrough Device Status

 

PITTSBURGH, June 2, 2022 /PRNewswire/ — Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The Company believes the FDA designation represents the first time an EHR company has been granted such designation.

 

(PRNewsfoto/Net Health Systems, Inc.)
(PRNewsfoto/Net Health Systems, Inc.)
Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is not granted solely on the severity of the device’s applicable condition. The submission must also meet one of the following criterion: the proposed device represents “breakthrough technology” as defined by the FDA; no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

 

Net Health’s Tissue Analytics Technology Pushes the Boundaries

 

“Finding ways to help our clients more quickly and accurately identify potentially life-threatening wounds and manage associated costs has been a priority for more than 20 years,” said Josh Pickus, CEO of Net Health. “The FDA designation highlights that Net Health is redefining EHRs as much more than simple documentation systems. Our intelligent AI-driven analytics solutions are pushing the boundaries of EHRs and helping change healthcare outcomes.”

 

Deployed by hundreds of healthcare organizations, including leading hospitals, health networks, and independent wound care clinics, Tissue Analytics’ novel diagnostic solution analyzes skin injury images and patient data using machine learning technology. This new level of analysis will allow Tissue Analytics to eventually provide new diagnostic elements as a complement to its current measurement generation imaging software, pending approval of its forthcoming marketing submission.

 

In granting the Breakthrough Device Status, the FDA recognized that the software could help wound care providers improve care by standardizing the diagnosis and care process of triaging patients with chronic, non-healing wounds with poor healing trajectories. In addition, the Agency noted that the “product will aid clinicians throughout the referral process with additional diagnostic information that can inform the wound care experts’ ultimate diagnosis and plan of care for chronic, non-healing wounds.”

 

“A first of its kind advancement like Tissue Analytics’ novel imaging functionality will make the clinical workflow for wound care safer, more effective, and ultimately more efficient,” said Alex Cadotte, Ph.D., ex-FDA Team Lead and now Director of Software and Digital Health at MCRA, LLC. “The FDA’s breakthrough designation acknowledges that Tissue Analytics is a first-of-its-kind device in Wound Care. The designation will also facilitate a collaborative conversation with FDA, which will ultimately be a win for public health.”

 

For more information on Tissue Analytics, visit https://www.nethealth.com/solutions/wound-care-tissue-analytics/ or https://www.tissue-analytics.com/ .

 

Net Health’s mission is to harness data for human health. Net Health solutions are trusted in over 23,000 facilities across the continuum of care. Our EHR software enables caregivers and their organizations to engage effectively with patients, streamline documentation, staff efficiently, secure maximum appropriate reimbursement and maintain regulatory compliance. Our unique approach to analytics seamlessly presents insights in clinical and operational workflows to improve care and business performance. Net Health is a portfolio company of The Carlyle Group, Level Equity and Silversmith Capital Partners. www.nethealth.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/net-healths-tissue-analytics-for-wound-care-granted-breakthrough-device-status-by-fda-301560059.html

 

SOURCE Net Health Systems, Inc.

Join us Thursday 30th June, for a clinical training session on improving hard-to-heal wounds with a specific focus on oedema and fibrosis, brought to you by Journal of Community Nursing in partnership with Thuasne.
‘Improving hard-to-heal wounds by managing oedema and fibrosis’ will be presented by Julie Stanton, Director of Nursing, Pioneer Wound Healing & Lymphoedema Centres.
You will have the opportunity to ask Julie any questions you may have during the real-time Q&A following the presentation. You will also receive a certificate of attendance upon completion of the session, which can be used towards your CPD revalidation portfolio.
Click ‘Going’ to register and receive further updates … read more

2022 is a time to heal, a time to unite and a time to innovate.

In September 2022 leading experts and delegates from around the world will come together to explore the current developments, innovations, practice and research that unite and heal at the Wounds Australia 2022 Conference.

A unique opportunity for professionals working in the field of wound management and care to participate in an exciting and challenging program. Delegates will actively engage with industry leaders and experts across a range of fields to reflect and critically assess the history of wound care, investigate current practise and the progress that has been made and explore opportunities for future innovations.

We are excited that the Wounds Australia 2022 Conference will enable delegates to reconnect, in person, after nearly two years of incredible challenges. The Conference will deliver a scientific and social program that is all about healing, uniting and innovating for the future … read more

A new study, “An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds,” published in the International Society For Pharmacoeconomics and Outcomes Research’s Value in Health journal (Jan. 2018) demonstrates the economic impact and full burden of chronic nonhealing wounds in the Medicare population. The study analyzed the Medicare 5% Limited Data Set for CY2014 to determine the cost of chronic wound care for Medicare beneficiaries in aggregate, by wound type, and by setting. Topline findings show that chronic wounds impact nearly 15% of Medicare beneficiaries (8.2 million) at an annual cost to Medicare conservatively estimated at $28.1 to $31.7 billion … read more

Abstract: Background. The evaluation and treatment of heel pressure injuries are a significant and expensive sequela of the aging population. Although the workup of patients with lower extremity tissue loss usually involves an assessment of the arterial blood flow by means of noninvasive vascular testing, the results may be misleading in patients with heel pressure injuries when the ankle-brachial index (ABI) does not provide direct information about perfusion of the rearfoot. The objective of this retrospective, observational investigation was to determine if noninvasive vascular testing provides accurate and reliable results in patients with heel pressure injuries … read more

The incidence of chronic wounds is increasing due to aging population and the augment of people afflicted with diabetes. Knowledge on the biological mechanisms underlying these diseases, there is a lot of medical technologies to conventionally treat the wound however wound healing differs from person to person … Several nanotechnologies have been developed demonstrating unique characteristics that address specific problems related to wound repair mechanisms. A review in Advance wound care journal, focused on the most recently developed nanotechnology-based therapeutic agents and evaluated the efficacy of each treatment in diabetic models … The success of topically administered growth factors in chronic wounds is limited. Due to their short in vivo half-life, low absorption rate through the outermost skin later around the wound, as well as rapid elimination by exudation before reaching the wound bed, might limit the efficacy of growth factors topical application … Conventional medications containing growth factors need to be applied in high doses and/or be repeatedly administrated over a long period, leading to important side effects and increasing the cost of the therapy. Presently, platelet-derived growth factor , fibroblast growth factor, and epidermal growth factor are widely studied for their application … read more

Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

 

Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced that it has been added to the new 2022 Consensus Guidelines of the International Surgical Wound Complications Advisory Panel (ISWCAP). The document, “Optimising Prevention of Surgical Wound Complications: Detection, Diagnosis, Surveillance and Prediction”1 presents an international consensus recommending approaches for the early detection, diagnosis and prediction of surgical wound complications in order to optimise incisional wound healing outcomes for patients.

 

Surgical wound complications remain a significant challenge for clinicians around the globe, representing one of the leading global causes of morbidity following surgery. The incidence of surgical wound complications, including surgical site infections (“SSI”), continues to rise. The development of a SSI is associated with a marked increase in morbidity, a 2-to 11-fold increase in mortality rate, and prolonged hospital stays2. Approximately 2-5% of surgical wounds in the US develop a SSI3 – 6 at an annual cost of up to $10 billion6-9. This includes extended hospital stays, readmissions and additional resources to manage complications.

 

In the consensus guidelines, the ISWCAP expert group noted that “the role of diagnostic technology is of particular importance in identification of surgical wound complications as it provides an objective means of detecting infection or another surgical wound complication without having to rely on clinician judgement – i.e. it helps to remove the subjective ‘human factor’ from identification and diagnosis”10.

 

MolecuLight’s point-of-care fluorescence imaging system is identified in the consensus because of its proven utility to quickly and non-invasively identify surgical site infections:

The ISWCAP expert group agreed that point-of-care fluorescence imaging is a diagnostic technology that could be of significant benefit in early identification of surgical site infections and may be a useful tool for early detection of other surgical wound complications10

 

The consensus also notes how fluorescence imaging is being used to guide detection of pathogenic activity and is providing useful insights and potentially changing current clinical assessment and diagnosis paradigms.11 Numerous studies have established the utility of the MolecuLight point-of-care technology in chronic wounds12, 13 (Le et al, 2020; Price, 2020). “The use of this technology in detection of SSI is an emerging field showing promising results”, notes the consensus. An example is “a recent study, ’Uncovering the high prevalence of bacterial burden in surgical site wounds with point-of-care fluorescence imaging’14, illustrated an 11-fold sensitivity in detection of infection by the MolecuLight device compared to clinical signs and symptoms alone (Sandy-Hodgetts et al, 2021)”.11

 

“Due to its ability to quickly and reliably detect bacterial burden at the point-of-care, fluorescence imaging using the MolecuLight device is positioned to change contemporary paradigms of post-surgical wound management”, says lead author Kylie Sandy-Hodgetts, PhD, Founder and inaugural President of the ISWCAP. “Early detection and prevention of surgical wound complications, including SSIs, are the ISWCAP’s key areas of focus. Novel diagnostic technology for earlier detection and intervention is imperative to optimise surgical wound outcomes. MolecuLight’s point-of-care fluorescence imaging of critical bacterial burden is at the forefront of that much needed initiative.”

 

References:

1Sandy-Hodgetts K et al, “Optimising prevention of surgical wound complications: Detection, diagnosis and prediction”, Wounds Intl., 2022
2Hatch MD et al. J Shoulder Elbow Surg. 2017;26(3):472-4777 3 Ban KA et al. J Am Coll Surg. 2017;224(1):59-74
4 Berrios-Torres SI et al. JAMA Surg. 2017;152(8):784-791 5 Institute CPS. Canadian Surgical Site Infection Prevention Audit. 2016 6 Si D et al. BMC Infect Dis. 2014;14:318
7 Badia JM, et al. J Hosp Infect. 2017;96(1):1-15
8 McLaws ML et al. J Hosp Infect. 2003;53(4):259-267
9 Sullivan E et al. Surg Infect (Larchmt). 2017;18(4):451-454 10 Sandy-Hodgetts K et al, Wounds International, 2022, pp. 9
11Sandy-Hodgetts K et al, Wounds International, 2022, pp. 16
12 L. Le, Advances in Wound Care, 25 Sep 2020 13N. Price, Diagnostics, 2020
14 Sandy Hodgetts, K. et al., Int Wound J. 2021;1–11.

 

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

For more information, contact:
Rob Sandler
Chief Marketing Officer
MolecuLight Inc. T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

 

Image (Download): https://moleculight.box.com/s/4tsj23g59tsesh8uwgnbhoow5aikbrjz

The pipeline for wound healing technologies includes lasers that kill bacteria and fluorescence imaging to aid in diagnostics.

 

FREMONT, CA: A skin wound is typically considered to be of little concern to the average person; however, a variety of disorders can cause or contribute to the severity of a wound that necessitates the use of specific technologies for proper healing.

Patients are predisposed to chronic wounds due to underlying factors ranging from malnutrition and stress to metabolic syndrome, necessitating intervention to accelerate a sluggish healing process.

In the United States, 3 percent of the population over the age of 65 has open wounds, and 2 percent of the entire population suffers from chronic wounds, according to a recent scholarly article that examined the magnitude of the problem.

Medicare cost forecasts for all wounds, including costs for infection treatment, range from $28.1 billion to $96.7 billion, with surgical wounds and diabetic ulcers being the most expensive to treat … read more

Treatment with the experimental protein replacement therapy PTR-01 promoted wound healing and decreased pain in people with recessive dystrophic epidermolysis bullosa (RDEB), new results from a Phase 2 clinical trial show.

The findings were presented by BridgeBio Pharma and its affiliate, Phoenix Tissue Repair, the therapy’s developer, at the annual meeting of the Society for Investigative Dermatology, in Portland, Oregon in May.

“In patients with recessive dystrophic epidermolysis bullosa (RDEB) even minor friction or trauma can cause debilitating blistering, tearing and scarring of the skin, along with severe pain … read more

Advancements in technology has helped healthcare enterprises deliver better wound care over the past few years.

 

Long-term care (LTC) wound management can provide a number of problems in achieving the ultimate aim of complete wound healing. Pressure ulcers, ischemic ulcers, venous ulcers, and diabetic foot (neuropathic) ulcers are all common conditions that healthcare providers see and treat. The risk of developing an ulcer should be examined in all residents. If a person is at high risk for developing an ulcer, staff should take aggressive measures such as nutritional support or pressure reduction. If an ulcer forms, the main goal is to heal it fully as soon as feasible and at a fair cost. Providers should distinguish between pressure, ischemia, venous, and neuropathic ulcers, keeping in mind that they might be combined and contain two or more components. Providers should assure appropriate foundational care, adequate nutrition, proper blood supply, edoema control, and great topical wound care in order to attain this goal. Topical wound care promotes wound healing by moisturizing the area and reducing necrotic tissue … read more

Researchers at the Technical University of Munich (TUM) have developed a film that not only protects wounds similar to the way a bandage does, but also helps wounds to heal faster, repels bacteria, dampens inflammation, releases active pharmaceutical ingredients in a targeted manner and ultimately dissolves by itself. This is all made possible by its dedicated design and the use of mucins, molecules which occur naturally in mucous membranes … read more

Diabetic foot ulcers (DFUs) are open sores or wounds caused by a combination of factors that include neuropathy (lack of sensation), poor circulation, foot deformities, friction or pressure, trauma, and duration of diabetes with complication risks. DFUs occur in 34% of people with diabetes,1 and approximately 14% to 24 % of patients with diabetes who develop a DFU will require an amputation … Diabetic complications cause 40% to 60% of nontraumatic lower limb amputations worldwide, and 80% of these amputations follow DFUs.2 However, a DFU is a preventable condition, despite being the leading cause of nontraumatic lower extremity amputations in the United States … read more

The role of wound cleansing in the management of wounds

 

This 30-minute presentation features learning opportunities that will provide in-depth instruction and demonstration in wound care treatments. After this webinar, the learner will be able to:

Identify the role of proper wound cleansing
Discuss how to select and use non-toxic wound cleansers
Describe advantages of collagen for managing a chronic wound
… read more

Researchers from the University of Tsukuba show that antibiotic resistance can be transferred between Staphylococcus bacteria by a process known as natural transformation … A bacteria called Staphylococcus aureus is widespread and generally harmless, but can cause infections known as “opportunistic infections”. These occur when the bacteria take advantage of certain situations, such as a weakened immune system or the presence of an open wound, to cause a harmful infection. These infections become particularly dangerous when the bacterial strain is resistant to treatment with antibiotics. Strains of Staphylococcus aureus known as MRSA, which are resistant to an antibiotic called methicillin, are becoming a significant problem worldwide. Now, a team from the University of Tsukuba have revealed the mechanism by which this methicillin resistance can be passed between bacteria … read more

providing the highest quality human tissue allografts available. We demonstrate our commitment to quality by collecting data from patient outcomes and analyzing the data for statistical significance, ensuring physicians make the most informed decision for the health of their patients. With the goal of addressing the root cause, rather than masking the pain, Regenative Labs birth tissue allografts provide an effective, non-addictive, non-invasive option for patients in debilitating situations.

 

Submit your contact information below and a representative will reach out shortly. Are you ready to create a new account? Click here to signup (please list Wound Care Weekly in the distributor field).

 

• Diabetic foot ulcers (DFU) are chronic wounds in the foot or feet associated with neuropathy and/or peripheral artery disease (PAD) of the lower limb in patients with diabetes mellitus.
• Reports from the Centers for Disease Control and Prevention show that in the United States there are nearly one in four adults living with diabetes, which indicates that a large number of Americans are at risk of DFU.
• DFUs will develop in up to 34% of patients with diabetes at some time in in their lives, and of those, approximately 15%–25% will require an amputation.
• Moderate or severe malnutrition has been identified in over half of patients with DFU, and malnutrition in DFU is correlated with increased lower-extremity amputation.
• Improvements in wound care therapy, including nutrition interventions, can reduce the financial burden of DFUs and increase life expectancy and quality of life.

… read more

BY BECKY DEY – from OCTOBER 2018

 

A wound dressing made from the silk protein sericin can help skin recover without scar tissue forming, new research shows … Millions of people worldwide suffer serious skin wounds caused by burns or trauma that are unable to self-heal. The main complication surrounding skin regeneration is scar tissue, which has different functional and mechanical properties to normal physiological tissue, often causing pain and discomfort for those affected … read more

Building on the previous success of education and awareness activities, Hamad Medical Corporation (HMC) recently joined the American Diabetic Awareness Alert Day to promote Diabetic Limb Salvage and launch a nationwide Awareness Campaign themed ‘Early diagnosis leads to early intervention: save a leg, save a life’ … The initiative was aimed at educating the general public and specifically diabetic patients at risk of feet ulcers and leg amputation, increasing their knowledge of signs and symptoms of this disease, and encouraging them to take care of their own feet … Diabetic foot is a substantial public health issue that affects people worldwide. Statistics show that twenty-five percent of people with diabetes are at risk of developing diabetic foot ulcers (DFUs). Limb salvage is the endeavour to save a limb from amputation, such as the foot … read more

BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022 between May 18 – 21, 2022 in Portland, Oregon … read more

GREENVILLE, S.C., May 18, 2022 /PRNewswire/ — A revolutionary temperature and pressure (TAP) sensing insole for diabetics, created by XtremedX, was recently named a TOP 20 New Diabetic Device for 2022 by the Diabetes Center Berne (DCB) in Berne, Switzerland. This is an international competition with the winners chosen by a panel of judges who are leading experts in diabetes care. XtremedX’s TAP sensing insole was one of only two products selected from the US as a leading innovative device for the management of diabetes.

 

Failure to heal a diabetic foot ulcer is a leading cause of hospitalization, amputation, disability, and death among people with diabetes. XtremedX TAP sensing insole for diabetics helps with daily monitoring of the feet, which can reduce diabetic foot ulcers by up to 85%. The sensor detects differences over time between both feet. Accumulated data from the sensor is then sent to the patient, caregiver, and/or physician via Bluetooth, Wi-Fi, or cellular technology for monitoring. An alert is provided by the insole at the first sign that an ulcer could potentially develop – often 4-6 weeks before the onset of symptoms. This allows the patient to take preventative measures to avoid an ulcer or further complications including amputation of lower extremities.

 

“We’re honored that we’ve been selected by the Diabetes Center Berne for this innovation challenge among all of the other incredible ideas and inventions to improve diabetes care,” said Carl Marshbanks, CEO of XtremedX. “It’s been an exciting time for our team, as we also recently were recognized as a first-place winner of the WeaRAcon 2022 international wearable robotics association conference this year. We’ve set out to create a product that will truly impact the management of diabetes and we’re glad to see that leaders in our industry believe in our mission as well.”

 

Each of the 20 companies with devices selected by Diabetes Center Berne participated in a pitch round this May where they presented their devices to a panel of DCB judges. These judges will select the top three finalists to participate in a bootcamp taking place on June 20 – 24 in Switzerland to develop their ideas with the help of the experts at DCB. After the bootcamp, a winner will be chosen on November 30 to be awarded $100,000 to fund further development of their innovation.

 

Diabetes Center Berne was created to advance diabetes care by bringing together some of the world’s leading experts to drive thought and innovation and provide access to clinical research facilities, laboratories, workspaces, and financial resources. Their innovation challenge provides an opportunity for companies with forward thinking ideas from around the world to make the greatest impact on the future of diabetes management.

 

ABOUT XTREMEDX

XtremedX LLC strives to develop the most technically advanced products, improving the quality of patient’s lives. They innovate technologically advanced products for Orthopedics, Surgery, DME (Durable Medical Equipment), and Smart Sensor Technology. Their mission is to create products that help to improve patient outcomes and reduce overall health care costs. As a Top Biomechanics Solutions Provider of 2021, they are also named a TOP 20 New Diabetic Device for 2022 by the Diabetes Center Berne, and a recipient of first-place award at the international wearable robotics association conference, WeaRAcon 2022. For more information, please visit www.xtremedx.com.

 

ABOUT DIABETES CENTER BERNE

Diabetes Center Berne is a private, independent Swiss foundation established in 2017. It helps research projects and business ideas to grow. Based in Switzerland, DCB provides expertise, access to clinical research facilities and its own laboratories and workspaces, and funding to projects around the world. It is located on the Insel Campus in the Swiss capital Bern. DCB works in close scientific partnership with the Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism of the Inselspital Bern (UDEM), a university hospital with a stellar international reputation in the field of diabetes technology.

 

Diabetes Center Berne
Freiburgstrasse 3
CH-3010 Bern
www.dcberne.com

 

SOURCE XtremedX

This article was originally published here

Longtime Congresswoman and former President and CEO of the Better Medicare Alliance, Allyson Schwartz, also joins Podimetrics’ Advisory Board

 

SOMERVILLE, Mass., May 12, 2022 /PRNewswire/ — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced four new leadership hires aimed at helping the company scale and support even more health plans and providers serving patients living with complex diabetes: Matthew Scalo as Chief Financial Officer, Kyle Bray as Chief Operating Officer, Kim Nguyen as Vice President of Financial Planning and Analysis, and Elizabeth Hogan Hamacher as Vice President of Clinical Services and Support. Podimetrics also added a new member to their advisory board, Allyson Schwartz, a long-time Congresswoman and also the former President and CEO of the Better Medicare Alliance.

 

These key hires and advisory board appointment follow Podimetrics’ recent announcement of their Series C. The company also experienced unprecedented growth in 2021, including doubling the patients under management with the Veterans Health Administration; doubling revenue for the third year in a row; and also doubling the size of the Podimetrics team. Dr. Jon Bloom, CEO and co-founder of Podimetrics, shared the following insights on the company’s growth trajectory for the year ahead: “We are in high-growth mode, and these leadership hires and the appointment of Allyson Schwartz to Podimetrics’ advisory board reinforce our focus on helping even more at-risk, underserved patients avoid the unnecessary health toll and financial burden associated with amputations resulting from complex diabetes.”

 

In just the first quarter of 2022, Podimetrics rounded out their leadership team with a series of strategic new hires that position the company for strong growth in the year ahead:

 

• Matthew Scalo, Chief Financial Officer — With nearly two decades of experience spanning banking and financial services, he most recently served as the senior vice president of finance at Cancer Treatment Centers of America;
• Elizabeth Hogan Hamacher, Vice President of Clinical Services and Support — A registered nurse with more than 12 years of clinical operations experience, she most recently served as senior director of clinical operations at ConsumerMedical; and
• Kim Nguyen, Vice President of Financial Planning and Analysis — With more than a decade of experience, she most recently served as associate vice president for financial planning and analysis for vRad (Virtual Radiologic).

 

The company’s latest addition to their advisory board, Allyson Schwartz, also brings unprecedented experience in healthcare, as well as policy. As a former member of the House of Representatives and former President and CEO of the Better Medicare Alliance, she is a nationally recognized leader on healthcare issues and was also instrumental in the passage of the Affordable Care Act. Schwartz shared the following insights about joining the advisory board at Podimetrics: “Podimetrics serves some of our nation’s most vulnerable patients — patients who have been ignored for far too long. It’s an honor to join their advisory board. The research and innovation they are leading will help drive a new preventive and proven approach to helping reduce amputations in patients living with complex diabetes.”

 

Podimetrics invented the SmartMat, which has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans. The SmartMat is the only easy-to-use, at-home mat that a patient steps on for only 20 seconds per day. The mat detects temperature changes in the foot, which are often a precursor to diabetic foot ulcers (DFUs). Patient temperature data from the SmartMat is then remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat is indicative of potential health issues, Podimetrics’ nursing team swiftly connects both with the patient and the patients’ provider.

 

For more information on Podimetrics and how its SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

 

About Podimetrics

Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with regional and national health plans and at-risk providers, such as the Veterans Health Administration, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit Podimetrics.com or follow us on LinkedIn and Twitter.

Contact: press@Podimetrics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/podimetrics-announces-expansion-of-leadership-team-with-four-new-strategic-growth-hires-301545591.html

BY LEONARD A. LEVY, DPM, MPH (from April 2021)

 

Podiatric Medical Practice, People with Diabetes, and the Relationship to Primary Care The typical practice of podiatric medicine includes a population that receives care on a more frequent basis than perhaps most patients seen by other medical specialists (e.g. surgeon, ophthalmologist, dermatologist, and otorhinolaryngologist). Patients who receive care from podiatric physicians very often do so several times yearly and often follow such a regimen over several years. Because of this, podiatric physicians with their education and training appropriately could be among the physicians who provide a major segment of primary care … read more (PDF)

Nancy Collins, PhD, RDN, LD, NWCC, FAND

 

Nutrition is a critical factor in the wound healing process, with adequate protein intake essential to successful healing. Patients with chronic and acute wounds, such as postsurgical wounds or pressure injuries, require increased protein to ensure complete and timely healing. Older patients with multiple comorbidities present a particular challenge. They often do not consume the necessary quality and quantity of dietary protein. In addition, this population may have a heightened stress response and resultant muscle loss due to a reduction in muscle protein synthesis. The all too frequent result is compromised wound healing, decreased ability to fight infections, and longer recovery time from illnesses and surgeries. It is imperative to address the increased protein needs of patients with wounds, especially older patients, to promote a full recovery … read more

“Uncaring: How the Culture of Medicine Kills Doctors and Patients”

 

by Caroline Fife, M.D.

 

I’ve been venting about my experiences with a broken healthcare system – both as a doctor and a caregiver. My friend, colleague, plastic surgeon and Renaissance man, Dr. Aron D. Wahrman alerted me to Robert Pearl’s book, Uncaring: How the Culture of Medicine Kills Doctors and Patients (a follow up to his book, Mistreated: Why We Think We’re Getting Good Health Care — and Why We’re Usually Wrong. I’ve recently talked about the experience of my friend and patient Dr. Richard Maddy, who lost both of his legs to cutaneous polyarteritis nodosa– in part because my pleas to start high dose steroids based on his clinical presentation were ignored, and my husband who died (albeit indirectly) from an adverse drug reaction that I diagnosed but for whom I could not the proper intervention from his inpatient team … read more

Author(s): Thomas Bjarnsholt, Val Edwards-Jones, Matthew Malone, Karen Ousey, Mark Rippon, Alan Rogers, Samantha Westgate, Sabine Eming, Isabelle Fromantin, Astrid Probst, Hans Smola, Hui-Mei Yang, Jiun-Ting Yeh, Steven Percival

 

Every wound type has the potential to develop serious infection, which in some cases can lead to chronicity, bone infections, long-term disabilities or even death. Bacteria within a wound will exist in either planktonic or biofilm forms, with treatment mostly by use of topical antimicrobials or antibiotics. Alarmingly, there is growing concern regarding the treatment of infection, caused by the rise of antimicrobial resistance in many common bacterial pathogens and the misuse of antimicrobial agents … read more

Chronic wound caused by diabetes is an important cause of disability and seriously affects the quality of life of patients. Therefore, it is of great clinical significance to develop a wound dressing that can accelerate the healing of diabetic wounds. Nanoparticles have great advantages in promoting diabetic wound healing due to their antibacterial properties, low cytotoxicity, good biocompatibility and drug delivery ability. Adding nanoparticles to the dressing matrix and using nanoparticles to deliver drugs and cytokines to promote wound healing has proven to be effective. This review will focus on the effects of diabetes on wound healing, introduce the properties, preparation methods and action mechanism of nanoparticles in wound healing, and describe the effects and application status of various nanoparticle-loaded dressings in diabetes-related chronic wound healing … read more

‘Best Technology Award’ and ‘Best Newcomer Award’

 

PRESS RELEASE MAY 10, 2022

DALLAS, May 10, 2022 (Newswire.com) – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, has been recognized for two prestigious European technology awards.

 

Spectral MD has been shortlisted for two awards at this year’s European Mediscience Awards for:

Best Technology Award
Best Newcomer Award

 

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognizing achievements in the life sciences industry. The European Mediscience Awards recognizes success and achievement amongst both private and publicly quoted companies throughout Europe and, as such, is attended by European life science companies and their corporate advisers, analysts, fund managers, commentators and peers.

 

Nooman Haque, Managing Director, Lifescience & Healthcare, Silicon Valley Bank, commented:

“The shortlist reflects the continuing strong growth of the European Mediscience industry and, in these challenging economic times, highlights those companies best positioned to manage through the turbulent cycle. We’re delighted to see such continuing enthusiasm for the industry.”

 

Wensheng Fan, CEO of Spectral MD, said:

“We are honored that Spectral MD has received nominations for ‘Best Technology Award’ and ‘Best Newcomer Award.’ This recognition further validates the promising potential of our DeepView® Wound Imaging Technology. DeepView® has the potential to be transformative in wound care. We look forward to building on this support and the exceptional results obtained thus far to expand into other important indications for our artificial intelligence for wound healing diagnostics.”

 

The winners will be announced at the celebratory dinner, to be held at the Hotel InterContinental, London W1, on Thursday, June 16, 2022.

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown”® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

Both Planktonic Bacteria and Bacterial Biofilms

 

Highlights

• In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria)
• XPERIENCE was shown to inhibit biofilm formation for up to five hours after application
• Study published in The Journal of Arthroplasty

 

JACKSONVILLE, Fla.–(BUSINESS WIRE)–Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty. The study, “A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty,” also found that XPERIENCE produced minimal cytotoxic effects to human tissue, allowing the solution to remain in the body without need for subsequent rinse. Additionally, XPERIENCE – cleared by the FDA for U.S. sale in April 2021 – was shown to inhibit biofilm formation for up to five hours after application.

 

Prosthetic joint infection (PJI) remains a significant burden in total hip arthroplasty (THA) and total knee arthroplasty (TKA) in the United States. Estimates indicate that, by 2030, the annual hospital costs related to PJI of the hip and knee will be $1.85 billion.1 Interventions to reduce or prevent the occurrence of PJI continue to be at the forefront of research efforts and commercial development.

 

“The minimum standard of care for irrigation in orthopedic surgical cases includes normal saline, but an increasing amount of literature in recent years has suggested that different solutions or additives may be needed to prevent PJI,” said orthopedic surgeon Ravi K. Bashyal, MD, the study’s lead author. “Combatting planktonic bacteria and the formation of biofilm is especially important given the high negative consequence of developing a PJI in the total joint arthroplasty setting.”

 

In the in vitro study, XPERIENCE demonstrated 4-log to 6-log reductions in planktonic bacteria after five minutes, and 4-log to 8-log reductions in biofilm bacteria. Future research using large-series in vivo data is necessary to further establish the irrigant’s efficacy in reducing primary and recurrent surgical site infections (SSIs). An estimated 1.5 million SSIs in the United States each year2 contribute $3.3 billion to the cost of U.S. healthcare.3

 

The study also found that XPERIENCE showed higher in vitro antimicrobial efficacy than three other commercially available adjuvants. The comparative treatments each reduced biofilm in all bacterial strains tested by approximately 1-log or less when the application times in their respective instructions for use were followed. However, XPERIENCE reduced biofilm by approximately 3-log to 8-log when used as directed.

 

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida, USA. Established in 2012, the Company’s primary focus is on the development and continued commercialization of products powered by its proprietary XBIO Technology. For further information visit: www.nextscience.com.

 

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science’s actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

 

¹Premkumar A., Kolin D.A., Farley K.X., et al. “Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States.” J Arthroplasty, 2021;36(5):1484-1489 e1483.

²Darouiche, R. (2019). “Surgical Site Infections.” Retrieved from: https://www.infectiousdiseaseadvisor.com/home/decision-support-in-medicine/ hospital-infection-control/surgical-site-infections

³Zimlichman, E., et al. “Health Care-Associated Infections. A Meta-Analysis of Costs and Financial Impact on the US Health Care System.” JAMA Intern Med, 173(22): (2013): 2039-46.

 

Contacts
Judith Mitchell
Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

 

Anthony Priwer
Dalton Agency
Phone: +1 615-515-4891
Email: apriwer@daltonagency.com

Hidradenitis suppurativa (HS) is a chronic autoinflammatory disease characterised by recurrent painful nodules, abscesses, sinus tracts and scars at apocrine gland-bearing sites. Treatment is universally challenging and sufferers may live with chronic and recurrent draining wounds. This review provides an up-to-date, evidence-based summary of HS, including clinical features, severity assessment, disease pathogenesis and current and emerging therapeutic approaches … read more

Part two of the EWMA document ‘The impact of patient health and lifestyle factors on wound healing’ focuses on two factors: physical activity and nutrition. In this paper, the pathophysiological understanding of how physical activity and nutrition either increase the risk for wounding or impact the healing process will be presented. We review current evidence for the effectiveness of interventions in improving healing outcomes and offer some recommendations for practice and further research. This part of the document should be read in conjunction with Part 11, which discussed stress, sleep, smoking, illicit drug use and alcohol misuse and described how some commonly used medications impact the healing process … read more

The outbreak of the coronavirus disease 2019 (COVID-19) led to events that significantly impaired the treatment and management of patients with chronic diabetes. Therefore, elective treatments at hospitals were cancelled and patients with chronic ailments were instructed to stay at home and minimise the time spent in public areas. The second was due to COVID-19-induced anxiety that deterred many patients from seeking care and adhering to periodic out-patient visits. In this study, we examined the short-term effects of the COVID-19 pandemic on patients with chronic diabetes who suffered from contaminated diabetic ulcers. We conducted a retrospective study with patients who had undergone amputations following diabetic ulcers during 2019-2020. The research group included diabetic amputees during the COVID-19 outbreak period ranging from March 2020 to December 2020. The control group included diabetic amputees from the corresponding period … read more

Rates of hospitalization and major amputations among racial and ethnic minority adults with diabetic foot ulcers decreased in states that adopted Medicaid expansion under the Affordable Care Act (ACA), according to researchers at the University of Arizona Health Sciences … Diabetic foot ulceration and amputation have serious health and financial implications, and the disproportionate rate at which it occurs among patients in lower socioeconomic groups is a largely recognized issue within the fields of medicine and vascular surgery … read more

HMP Global, the omnichannel leader in healthcare events and education, today announced the launch of a new program offering professionals who treat diabetic foot syndrome the opportunity to debate the most controversial topics in treatment options and gain knowledge from one another.

 

Great Debates & Updates in Diabetic Foot will be held December 2-3 in San Antonio, Texas. The unique, debate-style format will include dynamic presentations and interactive debates, while also diving into the long history of podiatry culture in San Antonio.

 

“The agenda will feature a mix of clinical updates and lively debates on provocative scientific topics impacting the field, including emerging concepts and treatment options for the diabetic foot,” said Dr. Lawrence A. Lavery, UT professor, board-certified podiatrist at UT Southwestern Medical Center, and event co-chairman. “We are excited to lead this inaugural event and provide a unique, interactive experience to the attendees, with several opportunities to network with faculty, industry, and colleagues.”

 

This year is the 50th anniversary of the podiatry residency program at the University of Texas Health Science Center in San Antonio, Lavery said, a milestone which will be celebrated at the GDU in Diabetic Foot event.

 

“There is a rich history of podiatry culture and diabetic foot research in Texas,” said Dr. Lee C. Rogers, event co-chairman and Chief of Podiatry and Associate Professor in the Department of Orthopedics at the University of Texas Health. “The Diabetic Foot Ulcer Classification System is a proven, effective, and widely used classification system for predicting hospitalization and lower extremity amputation. We look forward to discussing this, along with other important treatment tools and techniques, during the new program.”

 

GDU in Diabetic Foot is designed for the wide spectrum of medical professionals who diagnose and manage the diabetic foot, including podiatrists, wound care physicians, physical therapists, physicians-in-training, nurse practitioners, and physician assistants. The in-person meeting will allow attendees more opportunities for networking and engaging with colleagues and faculty experts.

 

“The GDU brand offers an educational experience unlike any other,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. “These unique, debate-style conferences provide a comprehensive learning experience covering the latest scientific updates and controversial issues emerging in different fields. We are excited to introduce the GDU brand through important education about managing and treating the diabetic foot.”

 

GDU in Diabetic Foot offers a maximum of 9 hours of continuing education credit. Exhibit space, attendee engagement options, and branding opportunities are available to organizations interested in participating in the event.

 

For more information or to register, visit gdudiabeticfoot.com.

 

About HMP Global
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Patients with a diabetic foot ulcer who received probiotic supplementation for 12 weeks experienced faster wound healing coupled with an improved glycemic and lipid profile compared with patients assigned placebo, according to findings from a randomized controlled trial … Sima Mohseni, of the infectious diseases and tropical medicine research center at Babol University of Medical Sciences in Iran, and colleagues analyzed data from 60 adults aged 40 years to 85 years with grade 3 diabetic foot ulcer, who randomly received either probiotic supplementation (n = 30) or placebo (n = 30) daily for 12 weeks … read more

Scott Freeman, PA-C, talks post-procedure infection prevention at the current New Wave Dermatology conference.

 

Scott Freeman, PA-C, in a video for Dermatology Times®, highlighted the importance of making sure patients adhere to good wound care at the Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference being held this week in Coral Gables, Florida. Additionally, he gave pearls on infection prevention.
… watch

To Elevate Awareness Of Hyperbaric Oxygen Therapy

 

BOCA RATON, Fla., May 2, 2022 /PRNewswire/ — CūtisCare, a leader in wound care and hyperbaric management, launches its second annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy. Hyperbaric Oxygen Therapy is an effective healing option for many different chronic conditions. Still, many go years without this treatment because they are unaware of treatment indications, benefits, and the patient selection criteria of hyperbaric medicine.

 

Hyperbaric oxygen therapy (HBOT) is a proven treatment option for wounds, infections, or injuries that have not responded to standard treatment. There are currently fourteen indications for HBOT recognized by the Centers for Medicare and Medicaid Services (CMS) and other third-party payors. Hyperbaric oxygen therapy is most commonly used for the treatment of diabetic ulcers of lower extremities, radiation injury to bone or tissue, compromised grafts and flaps, and chronic refractory osteomyelitis.

 

Hyperbaric Awareness USA™ designated May Hyperbaric Awareness Month. Throughout this month (and beyond), the Hyperbaric Aware™ campaign aims to promote hyperbaric oxygen therapy benefits, which will help people prolong lives, reduce amputations, and reduce the cost of care while improving quality of life.

 

There are more than eight million people in the United States who are living with chronic wounds. Twenty-five percent of the 34 million people in the US with Diabetes will develop a foot ulcer, possibly leading to amputation. Hyperbaric oxygen therapy provides necessary oxygenation, which is critical in preventing amputation.

 

In the US, almost half of the 17 million people diagnosed with cancer will receive radiation therapy, and 10-15% will experience late effects of radiation. Many patients who undergo radiation therapy discover a hidden complication that may not come to light until years after they complete treatments. Radiation therapy can restrict oxygen in the body’s healthy tissue which is needed for the tissue to thrive. If there is a break in the integrity of the tissue, infection and non-healing wounds can occur. Hyperbaric oxygen therapy is a treatment option for patients who suffer from late radiation tissue injury stimulating the growth of new blood vessels following radiation-induced damage.

 

CūtisCare Board Chairman and CEO Jim Patrick said, “As an industry leader, we are addressing the lack of awareness of hyperbaric oxygen therapy, a critical modality for chronic wound healing and limb preservation.”

 

The Hyperbaric Aware website, in collaboration with the Undersea and Hyperbaric Medical Society (UHMS) and physician leaders, will share articles, latest research, and expert insight for physicians, patients, and the general public.

 

About CūtisCare
Headquartered in Boca Raton, Florida, CūtisCare works with hospitals, academic medical centers, hospital systems, and physicians to design customized outpatient wound care and hyperbaric oxygen (HBOT) solutions. With more than 25 years of management experience, a commitment to research, and driven by ethics and a culture of compliance, CūtisCare collaborates with its partners to reach and heal people with chronic wounds.

 

For more information, visit https://cutiscareusa.com and https://hyperbaricaware.com

 

Follow us CutisCare LLC | LinkedIn and Hyperbaric Aware|LinkedIn.

Media Contact:

Kelly Caceres
kcaceres@cutiscareusa.com
904-446-0708
SOURCE CutisCare LLC

 

This article was originally published here

Joint provider with the South Carolina Podiatric Medical Association
Up to 20 continuing education contact hours
From $299/per night, Rate guaranteed until 05/23/22 or until room block is filled
Footprints in the Sand for Assistants: The Program will offer the ASPMA Radiology Certification Exam.
… register

available for purchase

Angela Gibson, MD, PhD, FACS, Aiping Liu, PhD, Collin L Tran, BS, Sameeha E Hassan, BS

 

Chlorhexidine (CHG) is ubiquitous in surgical perioperative care. In vivo studies of CHG cytotoxicity on human skin are lacking. Given the use of CHG for daily wound cares and as a presurgical scrub, including donor site preparation, we sought to identify if CHG cytotoxicity would persist in a clinically relevant in vivo human skin xenograft model … read more

Several iodine formulations have been used for wound care for ages, but still there exist a number of controversial issues regarding their uses in the present era. Many published studies are available for both povidone iodine (PI) and cadexomer iodine (CI) with conflicting outcomes due to different preparations used and different study types. PI has a broad spectrum of activity including antiseptic properties, anti-inflammatory properties, low cytotoxicity, and good tolerability with the absence of associated resistance. CI is an immobilized iodine molecule in a hydrophilic modified-starch polymer bead with the dual property of cleansing the wound by absorbing the exudate and bactericidal effect by sustained release of iodine molecules over the infected wound. The preparations comprising PI and CI improve wound healing and minimize the bacterial infestation or contamination in various chronic wounds, burns, and ulcers. This review narrates the comparison of CI and PI for the management of wounds in the context of biofilm reduction, wound size reduction, and granulation tissue promotion … read more

Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN® and genex®, when mixed with antibiotics

 

KEELE, England, April 12, 2022 /PRNewswire/ — Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held in Lisbon, Portugal on 23-26 April 2022. The company’s in-vitro research findings demonstrate the antimicrobial effectiveness of both STIMULAN® and genex® when mixed with antibiotics.

 

The first abstract demonstrates that STIMULAN® beads containing vancomycin and gentamicin were able to inhibit bacterial growth, when applied to tissue taken from diabetic foot infections, with zone of inhibition diameters ranging from 12-40mm.

 

The second abstract demonstrates the ability of genex® when mixed with combinations of vancomycin/gentamicin and vancomycin/tobramycin to prevent the formation of bacterial biofilms by MRSA, S. epidermidis and P. aeruginosa for up to 7 days on orthopaedic implant materials.

 

Both studies were co-authored by Julie Fletcher from the University of Exeter whom Biocomposites first funded in 2017 through the Daphne Jackson Trust, the UK’s leading organisation and independent registered charity dedicated to realising the potential of returners to research careers following a career break.

 

Dr Julie Fletcher, Research Fellow, The University of Exeter, said: “This research highlights the potential to use STIMULAN to achieve high local concentrations of antibiotic within poorly vascularised tissue to inhibit bacterial growth at a wound site, with the possibility of facilitating clearance of bacterial infection and improving wound outcomes. The genex research shows the potential to use genex as a carrier of antibiotics to prevent the formation of bacterial biofilm for up to 7 days on orthopaedic implants.”

 

Michael Harris, Chief Executive Officer of Biocomposites, added: “By presenting this new data at this important annual congress, we are pleased to further support the vital research being carried out by leading scientists. STIMULAN and genex are valuable tools for a surgeon and together help over 65,000 patients every year.”

 

STIMULAN® is the only calcium matrix antibiotic carrier approved to treat bacterial infection in surrounding soft tissue in Canada and for use in bone and soft tissue in EU, UK, and Saudi Arabia. STIMULAN® offers surgeons the flexibility to apply broad spectrum ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans – dramatically improving patient outcomes and redefining standard of care.

 

genex is a biphasic composite of exceptional purity that is specifically formulated to balance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture.

 

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

 

This article was originally published here

WoundZoom Digital Wound Management and MatrixCare provide seamless wound care communication for customers

 

STEVENS POINT, Wis., April 26, 2022 (GLOBE NEWSWIRE) — Perceptive Solutions, Inc., developer of WoundZoom Digital Wound Management, today announced its integration partnership with MatrixCare. The purpose of this partnership is to provide a seamless exchange of wound care data between WoundZoom and MatrixCare Customers’ EHR system.

 

As trusted integration partner with MatrixCare so Perceptive post-acute customers can leverage the benefits of WoundZoom while eliminating additional steps in their workflow. Data captured using WoundZoom at the bedside, such as precise wound measurements, images, and clinical assessments automatically sync to patients’ charts, creating a more efficient workflow and a complete patient record in the EHR.

 

“We are excited to add MatrixCare as a strategic EHR partner, the partnership will enable seamless and efficient data flow from our WoundZoom product platform into MatrixCare clinical charts. This enables healthcare facilities to more efficiently share valuable wound care data between both clinical and administrative team members within their EHR,” said Mark Lacerte, President of Perceptive Solutions. “Our innovative digital wound management solution enables clinicians to spend more time with patients through automated charting, wound imaging and elimination of the manual measurement process. We are excited to provide accessibility of WoundZoom to post-acute MatrixCare customers.”

 

About Perceptive Solutions

Perceptive Solutions modernizes the practice of wound care with technology-enabled systems designed to increase clinical efficiency, improve care quality, and mitigate risk. Integrating smoothly with your EHR, WoundZoom utilizes the latest AI and imaging technology to capture accurate wound images and measurements from your smart device, automatically prompt and document appropriate actions, and create a continuous, standardized clinical record across shifts, floors, and facilities. For more information, visit https://perceptivesol.com.

 

Media Contact

Karen Guzdzial
Director of Marketing
(727) 225 7944 karen.guzdzial@woundzoom.com

According to the United States (U.S.) Department of Health and Human Services, the Hispanic/Latino ethnic group includes any person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. In the U.S., states with the largest Hispanic populations are California, Texas, Florida, New York, Arizona, Illinois, New Jersey, Colorado, Georgia, New Mexico … Patient education materials in Spanish are paramount to wound care and hyperbaric services looking to offer the highest standards of clinical practice, and can help clinicians save time while engaging patients … read more

A topical gel that contains birch bark extract as the active ingredient — Filsuvez (Oleogel-S10) — has been recommended for approval for the treatment of skin wounds in patients with epidermolysis bullosa (EB) by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use … “The benefit of Filsuvez is its ability to promote healing of EB partial thickness wounds,” the EMA said in an announcement on April 22. “It is thought to work by modulating inflammatory mediators and stimulating keratinocyte differentiation and migration, thereby promoting wound health and closure,” the statement adds … read more